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Abstract 
Primary hyperparathyroidism constitute one of the most frequent endocrine diseases 
and arises mainly from parathyroid adenomas and carcinomas. 
The study of parathyroid physiology and pathology could highly benefit from the 
development of a continuous parathyroid cell line since the development of primary 
parathyroid cell cultures has proved to be extremely difficult, regardless from which 
specie the parathyroid gland is derived from. Many attempts were made to establish a 
parathyroid cell line derived from human or bovine parathyroid glands, however no 
successful cell line was ever established because functional parathyroid cells are very 
difficult to maintain in culture [1,2,3]. 
In this work, a rat clonal continuous parathyroid cell line, named PTH-C1, was stably 
transfected with the calcium-sensing receptor (CaSR) and the parathyroid hormone 
(PTH) genes in order to create a continuous parathyroid cell line with expression of the 
two main important genes of the parathyroid gland, CaSR and PTH genes. The PTH-C1 
cell line is a continuous cell line and endogenously presents the CaSR gene at low 
expression levels, in a similar manner to what is seen in human parathyroid tumours. 
On the other hand, the established PTH-C1 cell line with stable expression of both 
CaSR and PTH genes resembles the characteristics of normal parathyroid glands. 
Therefore, the two cell lines with low and high expression levels of the CaSR gene, 
were used to study the role of the CaSR in parathyroid tumourigenesis, analysing 
changes in protein expression, cell proliferation and modulation of PTH levels in 
response to variations in extracellular calcium Ca2+0 concentrations. 
The current work allowed obtaining several PTH-C1 clones with CaSR and/or PTH 
stable overexpression: two clones with stable expression of the CaSR gene; four clones 
with stable expression of both CaSR and PTH genes and nine clones with stable 
expression of the PTH gene. The subsequent characterization of the clones in terms of 
protein expression level, cell proliferation characteristics and ability to sense changes 
in Ca2+0 concentrations and modulate PTH levels, lead to the selection of the clones 
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with more similar characteristics to normal parathyroid glands. One of the selected 
clones presented higher cell population doubling times, indicative of a delay in cell 
proliferation that is consistent with a role for the CaSR in the inhibition of cell 
proliferation. Interestingly, another selected clone, with stable expression of both 
CaSR and PTH genes, showed ability to sense changes in Ca2+0 and to modulate 
intracellular PTH levels in response to those changes, resembling the regulation of 
intracellular levels of PTH observed in normal parathyroid glands. In contrast, PTH-C1 
cell line, with low endogenous expression of CaSR and PTH genes, showed deregulated 
cell proliferation and intracellular levels of PTH independent from Ca2+0 levels, which 
constitute similar characteristics to what is observed in parathyroid tumours. In 
conclusion, this work allowed to establish a unique continuous parathyroid cell line 
with stable overexpression of the two most important genes of the parathyroid gland 
and to study the role of the CaSR in parathyroid tumourigenesis.  
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1. Introduction 
1.1. Parathyroid gland physiology 
The parathyroid gland is typically formed by four small endocrine glands located in the 
neck, in the posterior surface of the thyroid gland. This endocrine organ develops from 
the endodermal pharyngeal pouches and the transcription factor GCM2 is a pivotal 
regulator of parathyroid gland development [4]. 
The glands are constituted by two types of cells, the parathyroid chief cells and the 
parathyroid oxyphil cells. The parathyroid chief cells are the most predominant in the 
gland and have the important function of producing PTH, whereas the oxyphil cells are 
present in a smaller number and have no known function [4] Regulation of Ca2+0  
homeostasis is the key function of parathyroid gland. This endocrine organ is able to 
detect changes in Ca2+0 levels, through the CaSR, which is able to sense even extremely 
small changes in Ca2+0 and modulate the secretion of PTH accordingly [4,5]. PTH 
subsequently acts in kidney and bone, increasing calcium (Ca2+) reabsorption in the 
kidney and the release of calcium in the bone.   
1.2. The calcium-sensing receptor 
The CaSR was cloned from the bovine parathyroid gland in 1993 by Brown E.M. and 
colleagues. This was a key discovery that established the calcium-sensing molecule 
responsible for sensing changes in Ca2+0 levels and to modulate PTH secretion 
accordingly. (4) The CaSR is a G-protein coupled receptor (GPCR) responsible for the 
maintenance of systemic Ca2+ homeostasis and is expressed in all the tissues involved 
in the calcium homeostatic system, such as the parathyroid gland, calcitonin-secreting 
C cells of the thyroid gland, kidney, bone and gastrointestinal tract [6] In addition, the 
CaSR was found to be expressed in other cells and tissues not directly involved in 
calcium homeostasis. In the parathyroid gland the CaSR senses the changes in Ca2+0 
levels and inhibits PTH secretion, resulting in increased Ca2+ excretion through the 
kidneys and decreased Ca2+ resorption from bone. Moreover, CaSR direct activation in 
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the kidneys inhibits Ca2+ resorption in the distal tubule, directly increasing urinary Ca2+ 
excretion. Finally, CaSR activation in calcitonin-secreting C cells of the thyroid gland 
inhibits bone resorption and stimulates the excretion Ca2+ in the kidney through the 
action of calcitonin hormone [5]. 
1.2.1. The structure of the CaSR 
The human CaSR is located in the chromosome 3q21.1, is formed by seven exons and 
encodes a protein monomer of 1078 amino acids [7]. The CaSR belongs to the family C, 
a unique family of GPCRs.  The metabotropic glutamate receptors (mGluRs) [8], the 
metabotropic GABAB receptors [9], a sub-group of putative pheromone receptors [10] 
and the taste receptors are all part of the subfamily C GPCRs [11,12]. The structure of 
the CaSR is common to other family C GPCR receptors and consists of seven 
transmembrane helices (TMDs), an extracellular N terminal domain (ECD) and an 
intracellular C terminal domain (ICD). The TMDs are formed by amino-acid residues 
613 from 862 and the ICD is composed by amino-acid residues 863 from 1078 [13]. The 
CaSR is characterized by a large ECD composed of 612 amino acids, with a sequence 
similar to bacterial periplasmic binding proteins, which possess a bi-lobe Venus flytrap 
domain (VFTD) [5, 14, 15]. The CaSR ECD has a critical role in co-translational 
processing [16], receptor dimerization [17] binding ligands [13, 18, 19] and 
transmission of activation signals through the TMDs. The VFTD presents calcium and 
amino acid binding sites [18, 20]. In addition, the VFTD contains the cysteines residues 
129 and 131, which form the stabilizing disulfide bonds that covalently link the CaSR 
monomers across the dimer interface in the cell surface [21]. Similarly to other GPCRs, 
the CaSR exists mainly in the form of a dimer [22].  Interestingly, the TMDs also contain 
Ca2+ binding sites, which are functional when the extracellular domain is absent 
[23,24]. However, it is not known whether Ca2+ binding sites located in the TMDs have 
actual access to Ca2+ or if only mediate CaSR activation when the full length receptor is 
present. Calcimimetics and calcilytics, the positive and negative CaSR modulators, 
respectively, have been found to bind in the TMDs. [25] The allosteric CaSR modulators 
are able to stabilize the active and inactive conformations of the receptor, when in 
presence of extracellular Ca2+. 
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The CaSR receptor from human parathyroid cells showed three CaSR specific 
immunoreactive bands of 120, 140 and 160 kDa, as well as additional bands of higher 
molecular mass (about 350KDa). The specie at 120 KDa corresponds to the non-
glycosylated form of the receptor, whereas the bands at 140 and 160 KDa correspond 
to species of the receptor N-glysosylated with mannose and carbohydrates, 
respectively [26,27] and N-glycosylation of the CaSR is important for its expression in 
the plasmatic membrane [27] and CaSR location in the plasmatic membrane is 
necessary for CaSR functional signaling. 
CaSR protein sequence is highly conserved between human, bovine, rat, mouse, rabbit 
and chicken, except for the amino-acid residues in the signal peptide and in the ICD 
from position 946. Thus, the conserved amino-acids in the ICD are probably important 
for normal CaSR function, which is supported by loss and gain of function mutations 
[28,29]. 
1.3. The parathyroid hormone 
The PTH is produced in the chief cells of the parathyroid gland. The biosynthetic 
pathway of PTH is first composed by preProPTH, an initial translational product that is 
then double cleaved enzymatically, with the consequent production of ProPTH and 
PTH, the secreted hormone [30,31]. An enzyme associated with microsomes is 
responsible for the cleavage of the preProPTH, the PTH precursor, into ProPTH, with 
the resultant removal of the prepeptide, which is then rapidly degraded [32]. The 
conversion of ProPTH to PTH occurs when ProPTH reaches the Golgi apparatus, 15 to 
20 minutes after biosynthesis [33]. The amino-acid sequence of the preProPTH is made 
of 115 amino acids, which are reduced to 90 amino acids upon cleavage to ProPTH that 
is finally cleaved to PTH, with 84 amino acids. Therefore, the amino-acid sequence of 
the PTH protein is formed by 84 amino acids and consists in the stored and secreted 
form of the hormone [34,35]. The cleavage of preProPTH into ProPTH and PTH occurs 
at the amino terminus of the protein. The sequences of the bovine and human 
prepeptides present 80% homology, while the rat prepeptide sequence is 64% 
homologous to the bovine and human. The ProPTH and PTH amino acid sequences 
present a higher homology, with 89% homology between the bovine and human and 
77% homology between rat and bovine/human amino-acid sequences [30]. The PTH 
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mRNA is formed by three exons, from which the exon I codifies the 5’UTR, the exon II 
codifies the prepro region of PTH and the exon III codifies the structural PTH and the 
3’UTR [36]. 
PTH is stored in secretory granules within the parathyroid gland and is rapidly secreted 
in the blood system when hypocalcemia is present, an action that is mediated through 
the CaSR. If hypocalcemia persists over time, the synthesis of new PTH increases, 
leading to the increase of long-term PTH stores. Therefore, the concentration of PTH in 
serum is established by the PTH released from intracellular granules and by the 
synthesis of new PTH [37,38]. Ca2+ is a key modulator of PTH serum levels, through the 
CaSR. Hypocalcemia induces the PTH secretion and synthesis, whereas hypercalcemia 
inhibits PTH secretion and synthesis and induces PTH degradation [39]. However, the 
Ca2+ is not the only factor influencing PTH serum levels, 1,25 dihydroxyvitamin D3 
(1,25(OH)2D3) and phosphorus also regulate PTH secretion and synthesis. 1,25(OH)2D3 
regulates PTH gene transcription and medium to long increases in phosphorus levels 
stimulate PTH secretion and synthesis, however, the mechanisms responsible by the 
sensitivity of parathyroid to phosphate concentrations are not known [40,41]. 
1.3.1. The regulation of PTH synthesis 
The synthesis of new PTH is primarily dependent of the availability of PTH mRNA and 
subsequently on the translation of the PTH mRNA by ribosomes. The increase of PTH 
mRNA depends on PTH gene transcription and PTH mRNA stability [34,42]. The 
transcription of the PTH gene is influenced by 1,25(OH)2D3, which represses PTH gene 
transcription. On the contrary, the increase in PTH mRNA synthesis in response to 
decreases in Ca2+0 is not due to increased PTH gene transcription, but to increased PTH 
gene stability.  Therefore, the control of PTH synthesis is post-transcriptional.  When 
hypocalcemia is present the rate of PTH degradation is reduced, increasing the PTH 
available to secretion [43,44]. The stability of PTH mRNA is regulated post-
transcriptionally, through protein-RNA interactions, such as interactions between 
trans-acting proteins and cis-acting elements located in untranslated regions (UTRs) of 
mRNA, which are targets to trans-acting proteins [45] An example of cis-acting 
elements is the adenine and uridine elements (AREs) [45] The k-homologytype splicing 
regulatory protein (KSRP), the AU-rich binding factor 1 (AUF1) and the upstream of N-
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ras (Unr) are examples of ARE-binding proteins [45]. The KSRP is a down-regulator 
factor of mRNA stability [46], whereas AUF1 promotes either deca or stabilization of 
mRNA [47] and Unr stabilizes PTH mRNA [48]. Therefore, the stability of PTH mRNA is 
determined through the interaction of ARE-binding proteins to AREs located in the PTH 
3’UTR mRNA, which is rich in adenine and uridine in all species [49,50]. It was 
identified a cis-acting type III ARE at the 3’UTR of rat PTH mRNA that determines PTH 
mRNA stability and PTH mRNA regulation by Ca2+ and phosphate. The identified ARE 
contains 63 nucleotides, from which 26 are conserved among species. The 63 
nucleotides ARE have demonstrated to be sufficient to regulate the stability of PTH 
mRNA and to confer PTH mRNA response to Ca2+ and phosphate [51]. UF1 and Unr 
bind and stabilize PTH mRNA, as was determined by UF1 and Unr overexpression and 
knockdown in HEK293 cells, with the consequent increase and decrease of PTH mRNA 
levels, respectively [52,53]. On the other hand, KSRP binds to the PTH mRNA 3’UTR 
ARE and decreases PTH mRNA stability. KSRP promotes the rapid degradation of PTH 
mRNA AREs through the interaction with the exosome [46]. PTH mRNA is also a 
substrate to the endoribonuclease polysomal ribonuclease 1 (PMR1), however, the 
silencing of KSRP or exosome components prevents the PTH mRNA cleavage from 
PMR1 [54]. In hypocalcemic parathyroid glands and chronic kidney failure rats the 
interaction between KSRP and PTH mRNA was decreased and the interaction between 
AUF1 and PTH mRNA was increased, which is in accordance with the higher levels of 
PTH mRNA present in these glands, indicative of higher PTH mRNA stability [49,50]. 
Therefore, KSRP and AUF1 are able to stabilize or destabilize PTH mRNA in response of 
changes in Ca2+ and phosphate. Consequently, the PTH mRNA half-life is regulated by 
the balance between the stabilizing action of AUF1 and the destabilizing protein KSRP. 
1.4. The calcium homeostasis 
1.4.1. The role of the CaSR in calcium homeostasis 
Ca2+ is an ion with several extremely important functions in the human body. For 
example, one of the functions of Ca2+ includes taking part in the mineralization of the 
skeleton and in the integrity of plasma membrane [5]. One of the most important 
functions of the Ca2+ is as a second messenger, in which Ca2+ binds to intracellular Ca2+ 
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sensors (i.e. calmodulin) and controls several cellular mechanisms, such as mitosis, 
gene expression and cell death [55,56,57]. These multitudine of functions highlight the 
necessity of maintaining adequate Ca2+ concentrations in the body, in order to provide 
sufficient Ca2+ for its several functions. The Ca2+0 concentration is maintained constant 
in the organism through the CaSR. This receptor can detect even extremely small 
changes in Ca2+0 from its normal level and is responsible for stimulate the other organs 
of the homeostatic system, such as kidney, intestine and bone, whose combined 
actions restore normal Ca2+0 levels [19,58]. The Ca
2+ homeostatic system is composed 
by three main components, Ca2+ sensors, hormones directly and indirectly controlled 
by Ca2+ sensors and cells within kidney [59], intestine [60,61] and bone [62] that 
control transport of Ca2+ in and out of the extracellular fluid. The CaSR is the most 
studied calcium-sensor and is expressed in all the organs involved in Ca2+ homeostasis, 
such as parathyroid chief cells, thyroid C-cells, kidney, intestine and bone [5]. PTH is 
the principal hormone involved in Ca2+ homeostasis. In the kidney, PTH increases Ca2+0 
reabsorption in distal renal tubules and the production of 1,25(OH)2D3 in proximal 
renal tubules. In the bone, PTH promotes the release of skeletal calcium. 1,25(OH)2D3 
is the biological active form of vitamin D3. The cycle of 1,25(OH)2D3 production starts 
with the synthesis of Vitamin D3 in the skin and intestine, from the diet. Then Vitamin 
D3 is 25-hydroxylated in the liver and subsequently 1-hydroxylated in the kidney, giving 
rise to 1,25(OH)2D3. The synthesis of the active form of Vitamin D3 is stimulated by 
PTH, hypophosphatemia and hypocalcemia and is inhibited by hyperphosphatemia, 
hypercalcemia and 1,25(OH)2D3 itself. 1,25(OH)2D3 is the second calcium-elevating 
hormone (PTH is the first), it enhances intestinal Ca2+ and phosphate absorption and 
stimulates bone resorption, thereby increasing Ca2+ levels [63]. Calcitonin is a potent 
calcium-lowering hormone in some species, such as rodents where it is responsible for 
decreasing bone resorption, but it is believed to be of minor importance in humans 
[64]. The last step of Ca2+ homeostatic system comprises the action of PTH and 
1,25(OH)2D3 in the kidney, intestine and bone. In the cortical thick ascending limb 
(CTAL) of Henle’s loop and the distal convoluted tubule (DCT), PTH and 1,25(OH)2D3 
increase tubular resorption of Ca2+, promoting renal Ca2+ conservation [65]. Plus, 
1,25(OH)2D3 stimulates transepithelial absorption of Ca
2+ in the small intestine. Finally, 
the bone has also an extremely important role in maintaining Ca2+ homeostasis [66]. 
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1.4.2. The system of calcium homeostasis 
The CaSR responds promptly to changes in Ca2+ levels, the receptor can sense even 
extremely small alterations in hypocalcemia and hypercalcemia. For example, when 
the extracellular Ca2+ decreases, the CaSR is able to sense it and sets in motion the 
intracellular signals to acutely increase PTH secretion and latter, PTH synthesis. 
Initially, PTH is released from intracellular stores within seconds and during about one 
hour with simultaneous decrease of PTH degradation. Then, PTH gene synthesis 
increases and parathyroid cellular proliferation increases for weeks to months [67,68]. 
Subsequently, the increase in circulating PTH levels exerts several actions in bone and 
kidney. In the bone, PTH increases the release of Ca2+, upon binding to PTH bone 
receptors. In the kidney PTH produces phosphaturia in the proximal tubule, increases 
Ca2+ reabsorption from the distal tubule and stimulates synthesis of 1,25(OH)2D3 from 
25(OH)D3 in the proximal tubule. The production of phosphaturia and the reabsorption 
of Ca2+ occur within minutes, allowing the correction of a brief period of hypocalcemia, 
whereas the production of 1,25(OH)2D3 requires elevated levels of PTH for several 
hours. 1,25(OH)2D3 also helps to reestablish normocalcemia, through its action on 
bone, where it promotes the release of intracellular Ca2+ and phosphate. Therefore, in 
hypocalcemia, normal Ca2+ is restored through the actions of PTH and 1,25(OH)2D3 that 
promote the increase in Ca2+0 levels from its actions in kidney, bone and intestines.  
The mechanisms that constitute the response to hypercalcemia of the Ca2+ 
homeostatic system are inverse to the responses initiated by hypercalcemia. High Ca2+ 
is sensed by the CaSR and inhibits PTH secretion, leading to decreased PTH levels in 
circulation, which increases excretion of Ca2+ through the kidney, induces 1,25(OH)2D3 
levels to decrease with consequent decreased absorption of intestinal Ca2+ and 
reduces the Ca2+ release from bone. Furthermore, in hypercalcemia the CaSR directly 
mediates Ca2+ excretion in the CTAL of the kidney.  Also, the CaSR mediates an increase 
in calcitonin, which has a hypocalcemic effect through the inhibition of bone 
resorption. However the hypocalcemic action of calcitonin is only relevant in the 
species in which the hormone is biologically active. In conclusion, it can be said that 
PTH and 1,25(OH)2D3 are the two elevating Ca
2+ hormones and that calcitonin is a Ca2+ 
lowering hormone [69]. 
17 
 
1.4.3. The regulation of PTH secretion by the CaSR in parathyroid 
cells 
In the parathyroid gland, hypocalcemia stimulates PTH secretion, PTH gene expression 
and cell proliferation, whereas hypercalcemia inhibits these cellular processes. The 
precise mechanisms that control PTH may involve heterotrimeric G proteins Gq and G11 
[70] with the phospholipase A2 (PLA2), lipoxygenase [71] and extracellular signaling-
regulated kinase 1 and 2 (ERK1/2) [72] pathways as possible downstream signaling 
cascades, but the precise mechanisms are still not known. Furthermore, actin 
polymerization increases in parathyroid cells upon stimulation with high Ca2+, which 
may create a physical barrier to exocytosis of PTH secretion from secretory granules 
[73]. PTH gene expression is regulated post-transcriptionally by the CaSR, as was 
explained above. [74]. Finally, the cellular and molecular mechanisms responsible for 
the control of parathyroid cell proliferation by the CaSR are not well understood. Cyclin 
D1 [75] and cyclin dependent kinase inhibitors, such as p21, [76] might be involved in 
the regulation of parathyroid cell proliferation. During hypercalcemia, the CaSR 
increases intracellular degradation of PTH, which decreases the biological active PTH 
(1-84) and reduces PTH secretion [77]. The expression of both CaSR and vitamin D 
receptor (VDR) genes is increased with the activation of the CaSR. The activation of the 
CaSR increases VDR mRNA expression, as well as, the activation of VDR increases CaSR 
mRNA expression, by a feed-forward mechanism. Moreover, the binding of 
1,25(OH)2D3 to the VDR decreases parathyroid cell proliferation and PTH gene 
expression. [78]. 
1.5. Pathologies of the parathyroid gland 
Diverse pathologies can affect the parathyroid gland, leading ultimately to primary and 
secondary hyperparathyroidism.  No mutations in the CaSR have been associated to 
the development of parathyroid tumours. However, mutations in the CaSR lead to 
diverse pathologies of calcium metabolism. Loss of function CaSR mutations result in 
familial hypocalciuric hypercalcemia (FHH), neonatal severe hyperparathyroidism 
(NSHPT) and primary hyperparathyroidism (PHPT) [79,80], whereas gain of function 
CaSR mutations result in autosomal dominant hypocalcemia (ADH) and Type V Bartter 
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syndrome [79]. Autoantibodies against the CaSR ECD also originate hypercalcemic 
disorders similar to FHH and hypocalcemic disorders similar to ADH. The central role of 
the CaSR in the regulation of Ca2+ homeostasis was highlighted through the discovery 
of the involvement of CaSR mutations in human disorders [81].  
1.5.1. Parathyroid Tumours 
Parathyroid adenomas and carcinomas constitute the two types of tumours of the 
parathyroid gland. Parathyroid adenomas are benign tumours, whereas parathyroid 
carcinomas are malign tumours. Both parathyroid adenomas and carcinomas are 
responsible for the development of primary hyperparathyroidism.  
1.5.1.1. Parathyroid adenomas 
Parathyroid adenomas are benign parathyroid tumours mainly formed by parathyroid 
chief cells as well as oxyphil cells in a smaller extent and are usually surrounded by a 
fibrous capsule. The nuclei in parathyroid adenomas are generally larger than in the 
non-neoplastic tissue, which is in accordance with the mitotic activity observed in 70% 
of the adenomas [82,83]. The majority of parathyroid adenomas develop from a 
monoclonal tumour (80%) and a minority from polyclonal tumours (5%) [84]. The most 
part of parathyroid adenomas are sporadic tumours with unknown etiology and only a 
small minority of parathyroid adenomas appear to be caused by mutations. For 
example, mutations in the MEN1 gene have been associated with parathyroid 
adenomas. Another gene whose expression has been related to the development of 
parathyroid adenomas is that encoding for the Cyclin D1. Overexpression of the cyclin 
D1 oncogene gene (CCND1/PRAD1) is present in 40% of the adenomas and accounts 
for one of the molecular abnormalities presented in these tumours [85]. The tumour 
suppressor gene MEN1 encodes a protein called menin and when is mutated lead to 
the development of multiple endocrine neoplasia type I (MEN1) [86]. Mutations in the 
gene MEN1 lead to the development of multiglandular parathyroid adenomas. [86,87]. 
The CaSR has also been associated with the development of parathyroid adenomas. 
The expression levels of the CaSR gene are decreased in parathyroid adenomas and 
the PTH-response to Ca2+0 is deregulated in these tumours, with a right-shift in the 
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calcium-response curve, supporting a role for the CaSR protein in the development of 
parathyroid tumours. 
1.5.1.2. Parathyroid carcinomas 
Parathyroid carcinoma is an extremely rare cancer with a rate of incidence of about 
0,005% from all cancers [88]. It accounts for less than 1% of primary 
hyperparathyroidism cases, being also a rare cause of primary hyperparathyroidism 
[89]. On contrary to parathyroid adenomas, parathyroid carcinoma occurs with an 
equal frequency in men and women and generally develops between 45 to 59 years of 
age, a decade earlier than parathyroid adenomas [89]. Parathyroid carcinoma can 
occur spontaneously or due to a genetic disease such as hyperparathyroidism jaw 
tumour syndrome (HPT-JT). [90, 91]. The HPT-JT is an autosomal dominant disorder 
characterized by the occurrence of fibro-osseous jaw tumours and parathyroid 
tumours. Approximately 10 to 15% of patients with HPT-JT develop parathyroid 
carcinomas. The disorder is also characterized by hyperparathyroidism due to the 
presence of multiple parathyroid adenomas. The disease is caused by mutations in the 
HRPT2 gene, which encodes parafibromin [92]. Genes involved in the regulation of the 
cell cycle such as cyclin D1, RB, BRCA and p53 were found to be abnormally expressed 
in parathyroid carcinomas [93]. Also, p27 and CaSR have been found to have a 
decreased expression in parathyroid carcinomas [94]. There are no other risk factors 
established for the development of parathyroid carcinoma and the etiology of this 
cancer is not known, with little knowledge available of the responsible molecular 
mechanisms.  
Conversely to parathyroid adenomas, which are normally asymptomatic of mildly 
symptomatic, the majority of parathyroid carcinomas are symptomatic due to the 
elevated PTH serum levels that are responsible for the hypercalcemia and the 
complications associated to the high Ca2+ levels [88,90]. Patients with parathyroid 
carcinoma present pronounced hypercalcemia and symptoms at bone and kidney 
levels, such as polyuria, renal colic, nephrocalcinosis, nephrolithiasis, bone pain, 
osteopenia and bone fractures [88]. Furthermore, the levels of serum calcium and PTH 
are usually higher in carcinomas than in adenomas. An important symptom of 
parathyroid carcinoma is parathyrotoxicosis, a hypercalcemic crisis due to the 
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extremely elevated Ca2+ levels. Calcimimetics such as cinacalcet can be used to treat 
the hypercalcemic crisis [95] However, some patients with parathyroid adenomas can 
also present the severe metabolic manifestations and the severe symptoms of 
hypercalcemia seen in parathyroid carcinoma, which difficult the diagnostic of 
parathyroid cancer [88]. In addition, a small part (<10%) of parathyroid carcinomas 
present normal Ca2+ and PTH serum levels and are asymptomatic, with a consequent 
delayed and difficult diagnostic [96]. The selected treatment is the surgical removal of 
the parathyroid tumour. However, parathyroid cancer has a recurrence rate of 49 to 
60% after the first tumour removal. Also, 15 to 30% of the patients initially present 
lymph node metastasis and 30% of the patients present distal metastasis in the lungs, 
liver and bone [97]. 
1.5.2. Primary and Secondary hyperparathyroidism 
Together, primary and secondary hyperparathyroidism constitute the third most 
prevalent endocrine diseases. Primary hyperparathyroidism typically arises from 
parathyroid adenomas and carcinomas, whereas secondary hyperparathyroidism 
results from parathyroid hyperplasia generally from chronic kidney disease. 
Parathyroid hyperplasia, adenomas and carcinomas are all proliferative lesions of the 
parathyroid gland.  
1.5.2.1. Primary hyperparathyroidism 
After diabetes and thyroid disorders, primary hyperparathyroidism is the most 
common endocrine disorder. Primary hyperparathyroidism has a rate of incidence of 1 
in 500 women and 1 in 2000 men over the age of 40 and it manifests prevalently in 
post-menopausal women (50-60 years old) [98]. However, the absolute rate of 
incidence of the disease depends on the population studied and the methods used. 
Parathyroid adenomas constitute the majority of proliferative lesions that lead to 
primary hyperparathyroidism (85%), immediately followed by parathyroid hyperplasia 
(15%), and rarely by parathyroid carcinomas (<1%) [99] The clinical presentation of the 
disease varies from the acute and severe bone and kidney symptoms to asymptomatic 
patients. Hypercalcemia and excessive PTH secretion are the main characteristics of 
primary hyperparathyroidism due to the action of the high levels of PTH on bone, 
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intestine and kidney, with consequent increased bone resorption, increased intestinal 
Ca2+ absorption, increased renal Ca2+ resorption, phosphaturia and increased synthesis 
of 1,25(OH)2D3. Consequently, patients with primary hyperparathyroidism typically 
present with hypophosphatemia and hypercalciuria in addition to hypercalcemia and 
increased PTH levels [100]. However, some patients present elevated Ca2+ levels but 
don’t have any visible symptoms of the disease, this is called asymptomatic primary 
hyperparathyroidism. A third group of patients with primary hyperparathyroidism can 
also present minor symptoms such as fatigue, weakness, depression and 
gastrointestinal symptoms [100]. The treatment of choice in primary 
hyperparathyroidism is parathyroid surgery, even for some patients with 
asymptomatic hyperparathyroidism, as long as the patient fulfills the criteria for 
surgery, according to the Guidelines for management of primary hyperparathyroidism 
issued by the third international workshop. However, when the guidelines for surgery 
are not met hypercalcemia and bone disease should be treated. Currently, the 
treatment can be performed with antiresorptive drugs that suppressed the increased 
bone turnover or calcimimetic drugs that lower PTH secretion and hypercalcemia 
[101,102]. 
1.5.2.2. Secondary Hyperparathyroidism 
Secondary hyperparathyroidism arises as a consequence of constant decreased Ca2+ 
levels and is characterized by a chronically increased secretion of PTH from the 
parathyroid gland [1]. The main cause of secondary hyperparathyroidism is chronic 
kidney disease (CKD). Moreover, hyperplasia of the parathyroid gland develops in 
secondary hyperparathyroidism, leading to increased PTH secretion and increased PTH 
serum levels, which contribute to the development of hypercalcemia, vascular 
calcifications and bone disease [103,104]. 
1.5.3. Hypercalcemic mutation-caused disorders 
1.5.3.1. Familial hypocalciuric hypercalcemia (FHH) 
FHH is an autosomal dominant inherited disorder caused by dominant heterozygous 
loss of function CaSR mutation. [19]. The inheritance pattern of FHH is autosomal 
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dominant. The disease is generally benign and is characterized by lifelong non-
progressive asymptomatic hypercalcemia, slightly elevated Ca2+ serum levels and 
mainly normal PTH levels [105,106]. In this condition, serum levels of 25-
hydroxyvitamin D (25OHD) and 1,25(OH)2D3 are within the normal values and the same 
occurs to bone mineral density (BMD) values [107,108]. In FHH parathyroid glands are 
generally normal or mildly hyperplastic and parathyroidectomy is not a required 
treatment because all the four parathyroid glands are involved in the hypercalcemia 
[108]. Consequently, it is of main importance to distinguish FHH patients from patients 
with primary hyperparathyroidism [100].  
In FHH mutations the Ca2+ concentration-response curve shifts to the right, so that the 
Ca2+ concentration needed to produce a half maximal (EC50) increase in intracellular 
Ca2+ release or in inhibition of PTH secretion is much higher than that required for the 
wild type CaSR receptor [108,78]. The major part of FHH mutations is located in the 
ECD [108] of the CaSR but FHH-mutations were also identified in the TMDs of the CaSR 
[108]. FHH mutations possibly inhibit CaSR signaling transduction by decreasing CaSR 
interactions with heterotrimeric G-proteins and with other components of the CaSR 
signaling transduction pathway [108,109]. Furthermore, about half of loss-of-function 
disease-causing mutations result in mutant CaSR receptors with trafficking defects. 
Mutants are unable to exit the endoplasmatic reticulum or the Golgi apparatus and 
reach the plasma membrane, with consequent reduced CaSR expression at the cell 
surface [110, 111]. Calcimimetic drugs have been shown to act has 
pharmacochaperones and facilitate correct protein folding, plasma membrane 
targeting and mutant trafficking [110]. 
1.5.3.2. Neonatal severe hyperparathyroidism (NSHPT) 
NSHPT is a life threatening disease, diagnosed in infants and characterized by severe 
neonatal hypercalcemia, elevated serum plasma PTH levels, parathyroid gland 
hyperplasia and hyperparathyroid bone disease [112]. If not treated, NSHPT results in 
the death of the patient. The treatment usually requires parathyroidectomy due to the 
extremely elevated hyperparathyroidism. NSHPT is considered to be the homozygous 
phenotype of FHH and occurs due to homozygous or compound heterozygous CaSR 
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mutations affecting both alleles of the gene [113]. So far, have been described more 
than 25 different CaSR mutations leading to NSHPT, from which more than 40% were 
nonsense and frameshift mutations predicted to originate a truncated CaSR receptor 
[108]. 
1.5.3.3. Autoimmune hypocalciuric hypercalcemia (AHH) 
Autoantibodies against the CaSR ECD have been found in patients with the clinical 
symptoms of FHH but without the presence of CaSR mutations. Autoantibodies against 
the CaSR may inhibit CaSR signal transduction and increase PTH secretion. These 
patients have been diagnosed with the autoimmune hypocalciuric hypercalcemia 
(AHH) disorder [114]. 
1.5.4. Hypocalcemic mutation-caused disorders 
1.5.4.1. Autosomal dominant hypocalcemia (ADH) 
Activating mutations of the CaSR constitute the cause of ADH. Over 70 different CaSR 
mutations, mostly heterozygous mutations, have been found to be associated with 
ADH. The mutated CaSR is responsible for a leftward shift of the Ca2+ concentration-
response curve, so that the calcium concentration needed to inhibit PTH secretion is 
lower than the Ca2+ concentration required to the wild type CaSR receptor. The 
patients are generally asymptomatic, in spite of the presence of hypocalcemia and 
increased urinary Ca2+ excretion due to the increased activation of the CaSR in the 
kidney.  
1.6. The molecular and cellular bases of parathyroid tumours 
Parathyroid adenomas and carcinomas present decreased sensitivity to Ca2+0 
concentrations, which lead to hypercalcemia and abnormally increased serum PTH 
levels due to abnormal inhibition of PTH reelase. The reduced expression levels of the 
CaSR found to be present in parathyroid adenomas and carcinomas have been 
implicated in these abnormal characteristics of parathyroid tumours.  
24 
 
1.6.1. Decreased CaSR expression in parathyroid tumours 
The CaSR mRNA and protein expression levels were found to be decreased or lost in 
parathyroid adenomas, parathyroid hyperplasia and parathyroid carcinomas. Whether 
this is the effect or cause of the tumourigenesis is not yet clear. However, the CaSR is 
thought to play a role in the development and progression of parathyroid tumours.  
Several studies have demonstrated that the expression levels of CaSR mRNA and 
protein are decreased in parathyroid adenomas, as well as in hyperplastic parathyroid 
glands from patients with uremic secondary hyperparathyroidism, compared with 
normal glands. For example, a study conducted by Corbetta et al. shown substantial 
reduction in CaSR mRNA and protein expression in parathyroid adenomas in 
opposition with tissues from normal parathyroid glands [115]. Another study using 
parathyroid samples from patients with primary hyperparathyroidism and normal 
renal function (single adenomas) and uremic secondary hyperparathyroidism (diffuse 
hyperplasia with or without nodule formations) revealed also a decreased amount of 
CaSR mRNA and protein [116]. A third study demonstrated a reduction of 64% in 
parathyroid adenomas from patients with primary hyperparathyroidism in comparison 
with normal biopsy from the same patient [117]. In addition, the study of Haven et al. 
suggests a role for the CaSR in prevention of malignant parathyroid tumours as the 
CaSR expression is decreased or absent in parathyroid carcinomas, compared with 
parathyroid adenomas and hyperplastic glands [118]. The presence of decreased CaSR 
expression in parathyroid tumours demonstrated in all these studies supports an 
important role for the CaSR in the development of parathyroid adenomas, parathyroid 
hyperplasia and also carcinomas. 
1.6.2. The CaSR and parathyroid cell proliferation in parathyroid 
tumours 
Uncontrolled parathyroid cell proliferation is a common feature in pathological 
parathyroid glands. Physiological activation of the CaSR appears to be related with 
suppression of parathyroid proliferation. Consequently, the CaSR seems to function 
has a tumour suppressor gene in the parathyroid gland [118,119,120]. Patients with 
inactivating CaSR mutations and mice homozygous for the CaSR knockout generally 
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exhibit marked parathyroid hyperplasia, indicative of the inhibitory role of the CaSR in 
parathyroid cell proliferation [119]. Furthermore, Haven et al. showed that the Ki67 
proliferation index is significantly higher in parathyroid carcinomas, where it is 
significantly correlated with down-regulation of CaSR expression, than in parathyroid 
adenomas and hyperplastic lesions [118]. In addition, also studies that evaluate CaSR 
expression and parathyroid proliferation in parathyroid glands from patients with 
secondary hyperparathyroidism caused by chronic renal failure revealed a decreased 
CaSR expression associated with the high proliferative parathyroid glands [120]. Plus, a 
recent work from Miller et al. using a rodent model of CKD characterized by 
parathyroid hyperplasia and increased PTH secretion demonstrated that treatment 
with the calcimimetic cinacalcet for 11 months mediated regression of parathyroid 
hyperplasia associated with decreased serum PTH. In addition, discontinuation of the 
treatment with cinacalcet induced the reestablishment of parathyroid hyperplasia and 
augment of PTH levels, further supporting the negative role of the CaSR in parathyroid 
proliferation [121]. 
1.6.3. Abnormal CaSR response to extracellular calcium in 
pathological glands 
In addition to the decreased CaSR expression and uncontrolled cell proliferation 
characteristics of parathyroid tumours, the ability of the CaSR to sense the changes in 
Ca2+0 also seems to be decreased in parathyroid tumours, has is shown by the week 
inhibition of PTH secretion in these pathological glands. This abnormal control of PTH 
secretion results in high PTH serum levels that if kept over time, generally lead to the 
development of hyperparathyroidism.  
1.6.4. Molecular mechanisms responsible for abnormal 
extracellular calcium sensing and uncontrolled parathyroid 
cell proliferation 
The molecular mechanisms that drive the loss of CaSR expression, as well as the 
mechanisms underlying abnormal PTH secretion in response to Ca2+0 concentrations, in 
parathyroid tumours are still not completely understood. One possible explanation for 
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the loss of CaSR expression was the loss of CaSR allele(s) on chromosome 3q leading to 
decreased CaSR mRNA levels observed in pathological parathyroid glands, however, 
this has turned out not to be the case [122,123]. Furthermore, no mutations in the 
coding region of the CaSR have been identified in parathyroid adenomas, hyperplasia 
or carcinomas, suggesting that mutations are not involved either in loss of CaSR 
expression or abnormal PTH release in these tissues [124,125]. For example, in the 
study of Hosokawa et al, 44 parathyroid tumours, formed by adenomas, carcinomas 
and primary hyperplasias, revealed absence of mutations in the CaSR coding region 
[125]. Similarly, Cetani et al, did not observe any mutations in the CaSR in 20 
parathyroid adenomas [124]. Also, the mechanisms responsible for the increased cell 
proliferation observed in parathyroid tumours are equally not known. More, the 
precise nature of CaSR down-regulation and parathyroid hyperplasia is not well 
understood. Another important point is that it still remains to be solved if the 
excessive secretion of PTH is due to the decreased CaSR expression or due to an 
increase in parathyroid cell mass, even if it is likely that decreased CaSR levels are 
responsible for the increased PTH secretion set-point [126]. Corbetta et al, have shown 
that the signaling pathways activated by the CaSR in parathyroid adenomas are similar 
to the signaling pathways activated in normal parathyroids, indicating that the CaSR 
possibly acts in a similar way in parathyroid adenomas and normal parathyroid glands 
[115]. The decrease of CaSR expression have been proposed as a possible factor 
responsible for the abnormal Ca2+ sensing in parathyroid adenomas. However, some 
parathyroid adenomas present normal expression levels of CaSR, but have reduced 
sensitivity to Ca2+ in vitro [115]. Another possible factor that may contribute to the 
defective calcium-sensing in parathyroid tumours are the lower levels of Gq proteins 
found in some parathyroid adenomas [115]. Also, the CaSR gene is encoded by two 
different 5’-untranslational exons, exon 1A and 1B, which originate two different 
mRNAs. In parathyroid adenomas the expression of exon 1A is decreased compared 
with normal parathyroid glands, which may also contribute to parathyroid 
tumourigenesis [125,126]. 
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1.7. Signaling pathways mediated by the CaSR 
1.7.1. Signaling pathways mediated by the CaSR in the parathyroid 
gland 
Impaired signalling through the CaSR is considered to be a major factor in promoting 
parathyroid hyperplasia and abnormal extracellular calcium sensing. As some 
parathyroid adenomas show a reduced sensitivity to Ca2+0 even when CaSR expression 
levels are normal, loss of CaSR expression might not be the only factor involved in the 
abnormal PTH secretion in parathyroid adenoma [115,127]. Defective CaSR signalling 
could also contribute to abnormal Ca2+0 sensing and unregulated PTH secretion in 
parathyroid tumours. A number of possible candidates have been proposed that could 
interact with the CaSR and modulate its signalling, such as cyclin D1, regulator of G 
protein signalling 5 (RGS5), caveolin-1, and Gαq Protein. 
1.7.2. Cyclin D1 as a modulator of CaSR signaling in the 
parathyroid gland 
Cyclin D1 belongs to the cyclin protein family and is involved in regulation and 
progression of the cell cycle.  It is overexpressed in 20-40% of parathyroid adenomas 
and in a subset of the tumours cyclin D1 becomes controlled by the 5’-regulatory 
region of PTH due to a chromosomal rearrangement and, as a result, it is 
overexpressed [128,129].  Furthermore, overexpression of cyclin D1 may also be 
attributed to a misregulation of the wnt/β-catenin signalling pathway, leading to 
accumulation of non-phosphorylated β-catenin in the cytoplasm and nucleus in a PTH-
producing parathyroid tumor cell line [130].  
It was suggested that cyclin D1 can interact with the CaSR and support development of 
parathyroid tumours by increasing parathyroid proliferation [131]. The role of cyclin D1 
in parathyroid tumourigenesis is supported by the study of Imanishi et al [128], who 
reported that a transgenic mouse model of hyperparathyroidism, that mimics the 
overexpression of cyclin D1 in parathyroid adenomas, presented with decreased CaSR 
expression levels, increased parathyroid cell proliferation and a right-shift in calcium-
dependent PTH response [128,132]. Furthermore, Corbetta et al. [131] showed that in 
parathyroid adenomas the CaSR inhibits cyclin D1 expression in the presence of growth 
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factors, such as basic fibroblast growth factor (bFGF) and epidermal growth factor 
(EGF), preventing the oncogenic actions of cyclin D1 in these tumours. Interestingly, 
the CaSR was unable to inhibit cyclin D1 activation in the absence of bFGF and EGF, 
supporting the existence of an interaction between the CaSR and these growth factors 
in the parathyroid gland[131]. 
1.7.3. RGS5 as a negative regulator of CaSR signaling in the 
parathyroid gland 
Koh et al. have recently shown that RGS5 is up-regulated in parathyroid tumours when 
compared with normal parathyroid glands [127]. RGS5 is part of the R4 subtype of the 
RGS proteins that inhibit signal transduction through regulation of heterotrimeric G 
proteins. Class C GPCRs, including the CaSR, are regulated by RGS proteins. In HEK-
CaSR cells, transiently expressing RGS5, ERK1/2 phosphorylation was inhibited, 
indicating that RGS5 is able to inhibit CaSR signal transduction in this heterologous 
expression system. Furthermore, RGS5-/- knockout mice displayed abnormally low 
plasma PTH levels with normal Ca2+ serum levels and normal responsiveness to Ca2+0. 
Therefore, it has been suggested that the RGS5 is a negative regulator of CaSR activity 
in parathyroid cells. It seems that RGS5 may compete with the CaSR in binding to Gαi 
and Gαq proteins preventing CaSR activation and thus maintaining the sensitivity of the 
receptor to deviations from normal Ca2+0 levels. Furthermore, overexpression of RGS5 
in parathyroid adenomas inhibited normal CaSR signalling and contributed to the 
abnormal Ca2+ sensing observed in parathyroid tumours. However, the normal Ca2+ 
serum levels present in the RGS5-/- mice indicates that the absence of RGS5 may not 
create a complete opposition to CaSR activity as it is seen in genetic conditions such as 
ADH and CaSR-/- mice [127]. 
1.7.4. The caveolae has a possible role in parathyroid signaling 
In many cell types, e.g. bovine parathyroid cells, the CaSR is found in caveolae, a 
plasma membrane organelle, where several signalling molecules are located, such as 
heterotrimeric G proteins, adenylate cyclase, Ras/Raf and protein kinace C (PKC) 
isoforms. Consequently, caveolae is thought to be involved in signal transduction. 
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Caveolins (caveolin-1, -2 and -3) are integral membrane proteins and constitute the 
major components of the caveolae with a possible important role in its structural 
organization. Also, caveolin-1 is thought to inhibit signal transduction and cell 
proliferation. The plasmatic membranes of bovine parathyroid cells are rich in 
caveolin, where the CaSR was found to be localized. Furthermore, the CaSR was found 
to co-localize with caveolin-1 independently from the Ca2+ level, and also with Gαq/11 
protein. Other signalling molecules such as PKC isoforms were also found to be present 
in the caveolae supporting its possible role as a signalling modulator. In addition, 
treatment of bovine parathyroid cells with high Ca2+ increases tyrosine 
phosphorylation of caveolin and of caveolin-enriched fractions [133]. More 
importantly, caveolin-1 is thought to inhibit signal transduction and cell proliferation. 
Approximately 62% of parathyroid adenomas express caveolin-1, and these tumours 
appear to have a better PTH response to Ca2+0 compared with those where caveolin-1 
expression is lower or lost [134]. 
1.7.5. The MAPK pathway in the parathyroid gland  
The CaSR is able to activate multiple signaling pathways. Binding of ligands to the CaSR 
triggers the activation of G proteins and leads to the activation of phosphatidylinositol-
specific phospholipase C (PI-PLC), causing accumulation of inositol 1,4,5-triphosphate 
(IP3) and 1,2-sn-diacylglycerol (DAG) and promoting rapid release of calcium from 
intracellular stores.The ERK1/2 pathway in bovine parathyroid and HEK293 cells is 
thought to be activated through both pertuxis toxin (PTX)-sensitive and PTX-insensitive 
mechanisms. In the parathyroid gland, activation of the CaSR by high Ca2+ results in PI-
PLC activation, through a PTX-insensitive mechanism mediated by Gαq/11, with 
subsequent formation of DAG and IP3 that culminates in the release of intracellular 
Ca2+ and PKC activation. PKC is then responsible for the stimulation of mitogen-
activated protein kinase (MAPK) cascade, which is followed by the phosphorylation of 
PLA2, with consequent release of free arachidonic acid (AA) that can be metabolized in 
two biologically active mediators such as hydroxyperoxyeicosatetranoic acid (HPETE) 
or hydroxyeicosatetranoic acid (HETE). The MAPK cascade can also be activated 
through a PTX-sensitive mechanism, presumably through an isoform of Gi. In this 
pathway, the CaSR is activated by high Ca2+ with a subsequent downstream activation 
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of a tyrosine kinase-dependent process with probable involvement of Ras or Raf. These 
intracelular signaling pathways are thought to be involved in the supression of PTH 
secretion [135]. 
1.7.6. The ERK1/2 signalling pathway is lost in parathyroid 
adenomas 
The MAPK are serine/threonine-specific protein kinases. Examples of MAP kinases 
include the ERK1 and ERK2, the p38-MAP kinase and the c-Jun NH2-terminal kinases. 
The phosphorylation of both tyrosine and threonine regulates and activates the MAP 
kinases. The role of MAP kinases in the regulation of cell growth and differentiation is 
well established. Other functions of activated ERK1/2 proteins include phosphorylation 
of cytosolic protein substrates, such as cytosolic phospholipase A2 (cPLA2), regulation 
of diverse enzymes and ion channels and phosphorylation of nuclear transcription 
factors, leading to gene expression regulation [135]. 
The MAPK are activated by many GPCRs. In accordance to this, the stimulation of 
bovine parathyroid cells with high Ca2+ leads to phosphorylation of ERK1/2 in a time 
and dose dependent manner [135]. Studies by Kifor et al. [134] have shown in freshly 
isolated bovine parathyroid cells that activated ERK1/2 colocalizes with caveolin-1 at 
the plasma membrane, whereas in bovine parathyroid cells cultured for 10 days they 
observed translocation of activated ERK1/2 and caveolin-1 to the nucleus and cytosol, 
in parallel with decreased expression of caveolin-1. ERK1/2 activation was increased 
both at low and high Ca2+0 in bovine cells cultured for 10 days, which is in accordance 
with the possible role of caveolin-1 as a negative regulator in the MAPK cascade. 
Similarly, in parathyroid adenomas, where caveolin-1 expression is decreased or lost, 
ERK1/2 was localised in the cytosol and nucleus, and a reduced ability for high Ca2+0-
mediated suppression of PTH secretion was observed. In the majority of the adenomas 
ERK1/2 was activated independently of Ca2+0 [134]. Thus, contrary to bovine 
parathyroid glands, ERK1/2 signalling pathway appears to be lost in parathyroid 
adenomas. 
Moreover, Corbetta et al. have reported that Gαq protein levels were lower in 
pathological parathyroid glands than in normal glands [115]. These results are 
31 
 
supported by another study in which increasing Ca2+0 concentrations and the CaSR 
agonist, gadolinium (Gd3+), failed to activate ERK1/2 in parathyroid adenomas [56]. 
Consequently, in parathyroid adenomas low expression of caveolin-1 and Gαq protein 
levels could possibly cause altered PTH release in response to Ca2+0 [115,134]. 
1.8. Calcimimetics and Calcilytics 
1.8.1. Calcimimetics 
Calcimimetics are molecular ligands able to increase CaSR sensitivity to Ca2+, leading to 
inhibition of PTH secretion from parathyroid cells through a left-shift in the Ca2+0-
concentration response curve, as was determined by a great number of in vitro and in 
vivo studies [136-139]. In addition, calcimimetics are also able to inhibit parathyroid 
secretion [140]. 
In the parathyroid gland, calcimimetics activate the CaSR, increasing the sensitivity of 
the receptor to Ca2+0 and thus inhibit PTH secretion and parathyroid cell proliferation. 
There are two different classes of calcimimetics, with distinct mechanisms of action: 
type I and type II calcimimetics. Type I calcimimetics are full agonists of the CaSR, i.e, 
are able to activate the CaSR and decrease PTH secretion in the absence of Ca2+. The 
natural CaSR ligand, Ca2+, other polyvalent inorganic cations magnesium (Mg2+), Gd3+, 
La3+, polyamines (spermine, spermidine and hexacyclin) and aminoglycosides 
(streptomycin, Bekanamycin, Gentamycin and Neomycin) constitute examples of type I 
calcimimetics. Contrary, type II calcimimetics, which are commonly called 
calcimimetics, are phenylalkylamine compounds that are able to stereoselectively 
activate the CaSR only in the presence of Ca2+, acting as positive allosteric modulators 
[141]. 
Cinacalcet, a type II calcimimetic, is currently approved to the treatment of secondary 
hyperparathyroidism in patients with advanced CKD as well as to treat hypercalcemia 
due to parathyroid cancer [142]. 
1.8.2. Calcilytics 
Calcilytics are small organic compounds able to block CaSR activity and stimulate PTH 
secretion from parathyroid glands and constitute the first antagonists of the CaSR. The 
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antagonistic response of calcilytics is seen in the inhibition of IP3 or intracellular Ca
2+. 
Calcilytics shift the concentration-response curve to Ca2+0 to the right without affecting 
maximal or minimal responses of the receptor to Ca2+0 [143]. In addition, calcilytics 
also stimulate PTH synthesis, partially through the stabilization of mRNA for prepro-
PTH, possibly to ensure that these antagonists deplete intracellular PTH stores [144]. 
The main scope of calcilytics is a possible use as therapeutic agents in osteoporosis, 
the rationale that the fast increase in PTH would stimulate bone turnover and bone 
formation. However, any of the calcilytics developed so far has proved to be of high 
use in the treatment of osteoporosis [145]. 
1.9. Parathyroid cell culture 
Presently, there is no primary parathyroid cell line since parathyroid cells are not easy 
to maintain functional in culture, independently from which specie they are derived 
from. Over the years, many attempts have been made in order to culture human and 
bovine parathyroid cells.  
The long term culture of human parathyroid cells is difficult because the culture 
became gradually contaminated by fibroblasts which proliferate faster than 
parathyroid cells, leading to the loss of these endocrine cells. In addition, the 
expression of CaSR gene is lost after a few days in culture, and the same is seen with 
the modulation of PTH levels in response to Ca2+0 and with PTH secretion [146]. 
Similarly, bovine parathyroid cells in long-term culture have proved impossible to 
maintain parathyroid function, the cultures quickly loose CaSR response to changes in 
[Ca2+0] and became senescent [147,148]. 
1.10. The PTH-C1 cell line 
The PTH-C1 is a clonal epithelial parathyroid cell line derived from rat and was 
subcloned from the PT-r cell line in the laboratory of Prof. Maria Luisa Brandi in the 
University of Florence. The PT-r cell line, a clonal epithelial parathyroid cell line derived 
from rat, was established in 1987 and similarly to human and bovine parathyroid cell 
cultures, did not show expression of the PTH gene, only parathyroid hormone-related 
peptide (PTHrP) was found to be expressed at the time [149,150,151]. However, 
recently, Kawahara et al. showed that the PT-r cell line has endogenous expression of 
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the PTH gene [152], which lead to the subcloning of the PT-r cell line, in order to select 
a clone with endogenous expression of the PTH gene. The clone obtained was named 
PTH-C1 and it endogenously expresses CaSR and PTH genes at mRNA level. However, 
both CaSR and PTH genes are expressed at a very low level in the PTH-C1 cell line, 
which together with the characteristic of continuous cell line, made of the PTH-C1 cell 
line an in vitro cell system similar to parathyroid tumours. Several other genes related 
with the parathyroid gland function were found in the PTH-C1 cell line, such as VDR, 
MEN-1, Caveolin-1, MAPK1, MAPK3, PTHR, PTHLP, ERα, ERβ, GH-R, HRPT2, LRP-5, 
SFRP4, PHEX, PRAD1, GALNT3, IL6, NPT2a and 1α-HYDROXYLASE. All the 
characterization studies of the PTH-C1 cell line were performed in the laboratory of 
Prof. Maria Luisa Brandi in the University of Florence, Italy.  .
34 
 
35 
 
2. The scope of the thesis 
The study of parathyroid gland physiology and pathology could be highly improved by 
the establishment of a parathyroid cell line with continuous characteristics of growth 
and maintained normal parathyroid function. However, the culture of primary 
parathyroid cells has proved to be difficult and presently, there is no such parathyroid 
cell line available to use as an in vitro cell model to parathyroid gland study. One of the 
aims of the present work consisted in stably overexpress CaSR and PTH genes in a rat 
continuous parathyroid cell line, named PTH-C1. Secondly, this work aimed to 
determine the role of the CaSR gene in parathyroid tumourigenesis.  
In the normal parathyroid gland, the CaSR is responsible for inhibit PTH secretion and 
synthesis, as well as parathyroid cell proliferation, at increased levels of Ca2+0. 
However, parathyroid tumours present abnormally increased cell proliferation and 
show PTH levels that are not regulated in response to Ca2+0 levels. This features 
presented by parathyroid tumours have been associated to a decreased expression of 
the CaSR in parathyroid adenomas and carcinomas. Still, the molecular and cellular 
mechanisms that lead to the changes in cell proliferation and PTH modulation in 
parathyroid tumours are far from being understood and to study these changes in a 
continuous parathyroid cell line could provide new data to the field.  
With this view, the PTH-C1 cell line with overexpression of CaSR and PTH genes 
together with the PTH-C1 cell line with low endogenous expression of CaSR and PTH 
genes, were used to study the role of the CaSR in parathyroid tumourigenesis, through 
the study of cell proliferation and modulation of PTH levels in response to Ca2+0 
concentrations. 
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3. Methods 
3.1. Cell culture 
3.1.1. Cell culture of PTH-C1 cells 
Non transfected cells were regularly cultured in growth medium (GM), composed by: 
F-12 Coon’s Modification cell culture medium (Sigma, St. Louis, MO, USA), 10% of fetal 
calf serum (FCS) (Sigma, St. Louis, MO, USA), and 100 IU/mL penicillin and 100 μg/mL 
streptomycin (Lonza, Verviers, Belgium), whereas transfected cells were cultured in 
GM enriched with 500µg/ml Zeocin (Life Technologies, Carlsbad, Ca, USA). The cells 
were seeded in 100 mm dishes at a density of 5 x 105cells/plate and passaged when in 
confluency. The media was refreshed every 3-4 days.  
3.2. Recombinant plasmid expression vectors 
3.2.1. Construction of recombinant plasmids for transient and 
stable transfections 
Two recombinant plasmids were constructed: a recombinant plasmid containing the 
CaSR cDNA and a recombinant plasmid containing the PTH cDNA.  
The mammalian expression vector used to construct both the recombinant plasmids 
was pcDNA3.1/Zeo(+) and it was a gift from Dr. Romuald Mentaverri, from the 
Universitè de Picardie Jules Verne, in Amiens, France.  
The pcDNA3.1/Zeo(+) is a mammalian expression vector of 5015 bp with a 
cytomegalovirus (CMV) promoter, which is a strong promoter able to mediate a high 
level of expression of the DNA inserted in the plasmid vector and is an adequate gene 
promoter for both transient and stable transfections. The pcDNA3.1/Zeo(+) plasmid 
expression vector contains a large multiple cloning site (MCS), which facilitates the 
insertion of the gene of interest into the plasmid vector. Furthermore, the plasmid 
vector contains a selectable Zeocin resistance marker that confers resistance to the 
antibiotic Zeocin, which can be used to select the mammalian cells that have stably 
integrated the gene carried by the plasmid, in the chromosome of the host cell. In 
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addition, the pcDNA3.1/Zeo(+) plasmid expression vector contains a bovine growth 
hormone (BGH) polyadenylation signal and transcription termination sequence, which 
improves mRNA stability and an ampicillin resistance gene for selection and 
maintenance of the plasmid expression vector in E. Colli bacterial cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. pcDNA3.1/Zeo(+/-) mammalian plasmid expression vector from Life 
Technologies.  
3.2.2. Construction of the CaSR pcDNA3.1/Zeo(+) recombinant 
plasmid vector 
The CaSR pcDNA3.1/Zeo(+) plasmid expression vector was constructed by sub-cloning 
with restriction enzymes. The CaSR gene used to construct the CaSR pcDNA3.1/Zeo(+) 
plasmid expression vector was a rat kidney CaSR cDNA full length (4113bp) gene 
inserted in a p-Sport bacterial plasmid vector (gift from Dr. Daniela Riccardi from 
Cardiff University, United Kingdom). The p-Sport bacterial plasmid vector was digested 
overnight with restriction enzymes between the NotI/KpnI/PvuI restriction sites in 
order to remove the CaSR cDNA from the plasmid and to create single strand 
overhangs in the 5’ and 3’ ends of the CaSR cDNA fragment. Simultaneously, the 
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pcDNA3.1/Zeo(+) plasmid expression vector was digested overnight with the 
restriction enzymes NotI/KpnI, in order to create single stranded overhangs in the 5’ 
and 3’ ends of the mammalian expression vector, which allowed to obtain 
complementary overhangs between the 5’ and 3’ ends of the CaSR cDNA and the 5’ 
and 3’ ends of the pcDNA3.1/Zeo(+) mammalian expression vector.  
Both the digested CaSR p-Sport plasmid bacterial vector and the digested 
pcDNA3.1/Zeo(+) mammalian expression vector were subsequently purified by gel 
electrophoresis in a 0,8% TAE agarose gel. The digested CaSR cDNA and the digested 
pcDNA3.1/Zeo(+) plasmid expression vector were isolated using the Montage DNA Gel 
Extraction kit (Millipore, Bedford, MA, USA), according with the manufacturer’s 
instructions, leading to gel dissolution and release of plasmid DNA fragments from the 
gel.  
Then, the digested CaSR cDNA was inserted into the digested pcDNA3.1/Zeo(+) 
plasmid expression vector through a ligation reaction with the T4 DNA ligase Enzyme 
(Promega, WI, USA) according to the manufacturer’s protocol. The T4 DNA ligase is 
responsible for the ligation of two complementary strands of DNA between two 
adjacent nucleotides and catalyses the ligation between the 5’- phosphate and the 3’- 
hydroxyl groups of cohesive or blunt DNA fragment ends.  
Finally, the ligation reaction obtained was transformed into bacterial cells JM109 E. 
Colli competent cells (Promega, WI, USA), in order to introduce the ligated plasmid 
DNA into the bacterial cells from E. Colli. The transformation reaction was performed 
by the heat-shock method, according to the manufacturer’s protocol. Briefly, 1,5ml 
Eppendorf microcentrifuge vials were chilled on ice prior to the reaction and JM109 E. 
Colli competent cells were thawed on ice for 5 minutes. Once the E. Colli competent 
cells were completely thawed, 100µl of bacterial cells and 10µl of ligation reaction 
were transferred for each chilled eppendorf microcentrifuge vial, pipetting while 
transferring. Vials were subsequently placed on ice for 10 minutes and were then heat 
shock for 45-50 seconds, in a water bath at 42°C and replaced on ice for 2 minutes. 
After addition of cold S.O.C medium (Life Technologies, Carlsbad, CA, USA) the vials 
were incubated at 37°C for 60 minutes with shaking. Finally 100µl of each 
transformation reaction was seeded in LB/ampicillin plates and incubated overnight. 
The day after, a colony was collected from the previous culture plates and inoculated 
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in 5ml of LB medium with the appropriate concentration of the antibiotic ampicillin 
and incubated overnight with shaking. Subsequently, the cells were collected by 
centrifugation in 15ml vials at 5400g for 10 minutes and the plasmid DNA was purified 
with the QIAprep Miniprep, according to the protocol “Plasmid DNA Purification using 
the Qiaprep Spin Miniprep kit and a Microcentrifuge”, (Qiagen, Hilden, Germany).  
3.2.3. Construction of the PTH pcDNA3.1/Zeo(+) recombinant 
plasmid vector 
The construction of the PTH pcDNA3.1/Zeo(+) plasmid expression vector occurred in a 
similar manner to the construction of the CaSR pcDNA3.1/Zeo(+) plasmid expression 
vector. The PTH gene was bought from Genscript (Genscript, Piscataway, NJ, USA) and 
consisted in a rat full length PTH cDNA (704bp). The rat PTH cDNA and the 
pcDNA3.1/Zeo(+) were simultaneously digested with the restriction enzymes 
HindIII/EcoRI, in order to create single stranded overhangs in the 5’ and 3’ ends of rat 
PTH gene and the mammalian expression vector and allow the formation of 
complementary 5’and 3’ ends between the fragments of the rat PTH cDNA and the 
mammalian expression vector. Subsequently, both the digested fragments of rat PTH 
cDNA and pcDNA3.1/Zeo(+) plasmid expression vector were purified by gel 
electrophoresis with a TAE agarose gel (0,8%) and isolated using the Montage DNA Gel 
Extraction kit, according with the manufacturer’s instructions. The rat PTH cDNA 
digested fragment was inserted into the digested fragment of the pcDNA3.1/Zeo(+), 
using a T4 DNA ligase, according with the manufacturer’s instructions. The ligation 
reaction obtained was transformed by the heat-shock method, using JM109 E. Colli 
competent cells, according to the manufacturer’s protocol. Finally, the transformed 
ligation reaction was purified with the QIAprep Miniprep, according to the protocol 
“Plasmid DNA Purification using the Qiaprep Spin Miniprep kit and a Microcentrifuge”. 
3.2.4. Verification of the construction of the recombinant plasmids 
The construction of the two recombinant plasmids, CaSR pcDNA3.1/Zeo(+) plasmid 
expression vector and PTH pcDNA3.1/Zeo(+) plasmid expression vector obtained with 
the QIAprep Miniprep was verified by PCR, digestion with restriction enzymes and 
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sequencing for the rat CaSR and rat PTH genes, as well as sequencing of the 
pcDNA3.1/Zeo(+) plasmid expression vector.  
3.2.5. Extraction and Purification of the recombinant plasmid DNA 
The plasmid expression vectors CaSR pcDNA3.1/Zeo(+) and PTH pcDNA3.1/Zeo(+) 
purified by the QIAprep Miniprep were analysed by PCR, digestion with restriction 
enzymes and sequencing , in order to confirm to be the correct recombinant plasmid 
constructs. The plasmid expression vectors were further amplified and purified by the 
Plasmid Midi Kit, according to the protocol “Plasmid or Cosmid DNA Purification using 
Qiagen Plasmid midi kit”, (Qiagen, Hilden, Germany).  The QIAprep Miniprep and the 
Plasmid Midi kit purify plasmid DNA through a modified alkaline lysis procedure and 
through the binding of plasmid DNA to the Qiagen resin, leading to the elimination of 
RNA, proteins and impurities of low molecular weight. The purified plasmid DNA was 
then eluted in an appropriated high salt buffer and subsequently precipitated in 
isopropanol to concentrate the plasmid DNA. 
3.3. Cell Transfection 
3.3.1. Transient Transfection 
The transient transfection was performed according to the tranfection protocol of the 
Attractene Tranfection Reagent (Qiagen, Hilden, Germany). On the day before 
transfection the cells were seeded in GM, in 24 well plates with an approximate cell 
density of 8 x 104 per well and incubated at 37°C, 5% CO2 overnight. On the day of 
transfection, the cells were approximately 80% confluent. A transfection mixture 
composed of CaSR pcDNA3.1/Zeo(+) plasmid cDNA, transfection reagent and F-12 
Coon’s Modification medium without serum, proteins or antibiotics to a total volume 
of 60µl per well, was prepared. The transfection mixture was incubated at room 
temperature for 15 minutes to allow the formation of transfection complexes. 
Subsequently GM was added to the transfection mixture to a total volume of 500µl per 
well. Then the media of the 24 well plate was aspirated and the final transfection 
mixture was added to the cells (500µl per well). The cells were incubated at 37°C and 
5% CO2 overnight. Finally, 24h after transfection the media was removed, the cells 
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were recovered in a pellet, which was stored at -80°C for subsequent molecular 
analysis.  
3.3.2. Determination of cells sensitivity to the antibiotic zeocin 
The determination of the sensitivity of the PTH-C1 cells to the antibiotic Zeocin was 
performed according with the protocol provided by Life Technologies, manufacturer of 
the Zeocin, selection reagent.  
The cells were seeded in GM, in a 6 well plate with an approximate cell density of 2 x 
105 cells per well and incubated overnight at 37°C and 5% CO2. On the next day the cell 
culture medium was aspirated and replaced by DME/F12 Base Medium (Sigma, St. 
Louis, MO, USA), 10% FCS, 100 IU/mL penicillin and 100 μg/mL streptomycin, with five 
different concentrations of the antibiotic zeocin: 50µg/ml; 100µg/ml; 250µg/ml; 
500µg/ml and 1000µg/ml. Culture media was refreshed twice a week. The cells were 
growth for 20 days and it was observed which concentrations of zeocin were able to 
kill the cells. At the end of the experiment the cells were stained with acridine orange 
and ethidium bromide in order to visualize the dead and live cells.  
3.3.3. Cell staining with Acridine Orange and Ethidium Bromide 
A solution of acridine orange and ethidium bromide was used to differentiate live and 
dead cells. The live cells are stained with acridine orange and the dead cells with 
ethidium bromide. In a fluorescence microscope, live cells stained with acridine orange 
show a green colour, while dead cells stained with ethidium bromide show a red 
colour [153]. 
Cell culture media was removed from the plates and the cells were washed twice with 
cold Dulbecco’s Phosphate Buffered Saline (DPBS) (Lonza, Verviers, Belgium). A 
solution of acridine orange/ethidium bromide with a concentration of 2mg/L of 
acridine orange and 2mg/L of ethidium bromide was added to the cells in an 
appropriate volume, sufficient to cover the surface of the cell culture wells. The 
solution of acridine orange and ethidium bromide was removed from the plates after a 
few seconds of contact with the cells. The cells were recovered with GM and were 
observed in fluorescence with fluoresceine and rodamine filters using an Axiovert 200 
M inverted microscope (Zeiss, Oberkochen, Germany). 
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3.3.4. Stable Transfection 
The ultimate goal of stable transfection is to integrate permanently the gene carried by 
the plasmid expression vector into the chromosome of the host cell. The stable 
incorporation of the transfected gene into the chromosome of the host cell is a rare 
event that occurs randomly by non-homologous recombination between the plasmid 
expression vector and the chromosome of the host cell. Subsequently, the small 
number of stably transfected cells is usually selected by resistance to an antibiotic 
marker carried in the transfection plasmid. The level of expression of the transfected 
gene is a function of the site of integration in the host cell chromosome and of the 
number of copies of the gene that were stably integrated.  
The plasmid expression vectors used for stable transfection were CaSR pcDNA3.1/Zeo 
(+) and PTH pcDNA3.1/Zeo(+). The stable transfection was performed according to the 
tranfection protocol of the Attractene Tranfection Reagent. On the day before 
transfection the cells were seeded in 24 multiwell plates with an approximate cell 
density of 8 x 104 cells per well and incubated at 37°C, 5% CO2 overnight. On the 
following day the cells were about 80% confluent and four different transfection 
mixtures were prepared: one mixture composed of CaSR pcDNA3.1/Zeo(+) plasmid 
expression vector, Attractene reagent and Coon’s medium without serum, proteins or 
antibiotics to a total volume of 60µl per well; a second mixture of PTH 
pcDNA3.1/Zeo(+) plasmid expression vector, Attractene reagent and Coon’s medium 
without serum, proteins or antibiotics to a total volume of 60µl per well, a third 
mixture composed of CaSR pcDNA3.1/Zeo(+) plasmid expression vector, PTH 
pcDNA3.1/Zeo(+) plasmid expression vector, Attractene reagent and Coon’s medium 
without serum, proteins or antibiotics to a total volume of 60µl per well and a forth 
mixture composed of pcDNA3.1/Zeo(+) plasmid expression vector, Attractene reagent 
and Coon’s medium without serum, proteins or antibiotics to a total volume of 60µl 
per well. All the four mixtures were incubated at room temperature for 15 minutes to 
allow the formation of transfection complexes. Subsequently GM was added to each 
transfection mixture to a total volume of 500µl per well, in order to form the final four 
transfection mixtures. Then the cell culture media on the 24 multiwell plates was 
aspirated, each final transfection mixture was appropriately added to the cells (500µl 
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per well) and the cells were incubated at 37°C and 5% CO2. 48h after transfection the 
media was replaced by GM enriched with 500µg/ml of antibiotic Zeocin (selective 
culture medium). The cells were growth in this selective culture medium until reach 
cell confluency and were subsequently detached from the 24 multiwell plates, 
collected, transferred to 6 multiwell plates and finally expanded to 100mm dishes. A 
cell pellet was collected from the heterogeneous populations of cells stably 
transfected with the CaSR gene, the PTH gene, both CaSR and PTH genes and the 
pcDNA3.1/Zeo(+) plasmid expression vector, to molecular . All the heterogeneous 
populations of cells, except the population stably transfected with the 
pcDNA3.1/Zeo(+) plasmid expression vector, were subsequently cloned by the limiting 
dilution method and frozen in liquid nitrogen.   
3.3.5. Cell Cloning 
The heterogeneous population of cells stably transfected with the CaSR and/or PTH 
genes were cloned by the limiting dilution method, in order to select clones stably 
expressing the CaSR gene, clones stably expressing the PTH gene and clones stably 
expressing both CaSR and PTH genes. The cells were seeded in GM at a concentration 
of 10 cells/ml in a 96 well plate, where were seeded 100µl per well, with the aim of 
obtaining one single cell per well. The cells were incubated overnight at 37°C and 5% 
CO2 and counted on the next day in an Axiovert 200 M inverted microscope. Each well 
was carefully observed and only the wells where a single cell was present were 
considered to be single clones and were subsequently observed every day for 
approximately two weeks until the cells reach confluency. Subsequently, the cells were 
detached from the 96 multiwell plates, collected, transferred to 24 multiwell plates, 
growth until cell confluency, detached from the 24 multiwell plates, collected, 
transferred to 6 multiwell plates, growth until confluency, detached from the 6 
multiwell plates, collected and finally expanded to 100mm dishes. A cell pellet from 
each cell clone obtained was collected for molecular analysis and all the obtained 
clones were frozen in liquid nitrogen. 
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Figure 2. Schematic image of the procedure to obtain PTH-C1 clones with stable 
expression of CaSR and/or PTH genes. 
3.6. RNA Isolation 
Total RNA was purified from the cell pellets previously stored at -80°C using TRIZOL 
RNA isolation protocol (Invitrogen, CA, USA). 1ml of TRIZOL was added to each cell 
pellet, which was dissolved in the TRIZOL by pipetting. 0,2ml of chloroform (J.T. Barker, 
Deventer, Holland) were added, the lysates were vortexed for 15 seconds and 
centrifuged at 12,000 g for 10 minutes at 4°C. Centrifugation resulted in the formation 
of three phases in the mixture: a lower phenol-chloroform phase, an interphase and an 
upper aqueous phase. RNA is dissolved in the upper aqueous phase, which was 
collected and transferred to a clean 1,5ml Eppendorf tube. The aqueous phase was 
mixed with 0,5ml of isopropanol (Carlo Erba Reagents, Rodano, Italy) for 2 minutes, in 
order to precipitate the RNA, and was then centrifuged at 12,000 g for 10 minutes at 
4°C. The small pellet of precipitated RNA obtained was washed with 1ml of 75% 
ethanol (J.T. Barker, Deventer, Holland) and centrifuged at 12,000g for 5 minutes at 
4°C. The supernatant was carefully removed and the pellet was left to air-dry. Finally, 
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RNA pellet was dissolved in diethylpyrocarbonate (DEPC)-treated water and stored at -
80°C until use.    
The isolated RNA was quantified using a Nanodrop (Nanodrop ND-100 v3.3 
Spectrophotometer, Thermo Scientific, Delaware, USA).  
The quality of the isolated RNA was analysed by agarose gel electrophoresis (0,8%) 
with GelRed nucleic acid staining (Biotium). 1µl of RNA was used in the agarose gel 
electrophoresis. The Marker used during the runs was MVIII (Roche, Switzerland, 
Europe). 
Contaminating genomic DNA was removed with DNA-free kit (Ambion inc, Huntingdon, 
UK). The inactivating agent was added to the reaction after incubation at 37°C for 30 
minutes. The samples were then centrifuged to remove the inactivating agent. 
3.7. Polymerase Chain Reaction (PCR) 
One μg each of the total RNA was used for the reverse transcription reaction with 
QuantiTect Reverse Transcription kit (Qiagen, Hilden, Germany). 
The cDNA samples obtained were then amplified by PCR reactions with Go-Taq DNA 
Polymerase (Promega, WI, USA) to verify the expression of CaSR and PTH genes. The 
conditions utilized for the PCR reaction were: initial denaturation step at 95°C for 5 
min, 40 repeated cycles composed of denaturation at 95°C for 40 s, annealing at 
specific temperature for each tested gene for 40 s, extension at 72°C for 90 s and a 
final extension step at 72°C for 6 min. The rat CaSR cDNA was amplified using the 
following set of primers: sense 5’ – GATCAAGATCTGAAGTCAAG – 3’ and antisense, 5’ – 
CCAGTGTCATGTTGGGAAGA – 3’. The rat PTH cDNA was amplified using the following 
set of primers: sense, 5’-TCCAGTTCATCAGCTGTCTGGCTT-3’ and antisense, 5’-
AAGGAGACAAACTGCCAGCATGAG-3’. Control PCR was carried out with the 
amplification of rat β-actin cDNA using the following set of primers: sense, 5’- 
CAACCTTCTTGCAGCTCCTC-3’ and antisense, 5’- TTCTGACCCATACCCACCAT-3’. The size 
of the amplified DNA was verified in a 2% agarose gel. The Marker used was MVIII 
(Roche, Switzerland, Europe). 
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3.8. Real-Time Polymerase Chain Reaction (qPCR) 
qPCR was performed using KAPA PROBE FAST qPCR kit (KapaBiosystems), according to 
the manufacturer’s instructions. There were used TaqMan specific probes for the CaSR 
and PTH genes, as well as for the RPS18, which was used as an internal control. The rat 
CaSR cDNA was amplified using the following set of primers and probe: sense 5’-
GTGACCTTCGATGAGTGTGGTGAT-3’, antisense 5’-TTGAACACAATGGAGCCGTCCTCT-3’ 
and probe 5’-/56-FAM/ACTATTCTA/ZEN/TCATCAACTGGCACCTCTCCC-3’. The rat PTH 
cDNA was amplified using the following set of primers and probe: sense, 5’-
TCCAGTTCATCAGCTGTCTGGCTT-3’, antisense 5’-AAGGAGACAAACTGCCAGCATGAG/-3’ 
and probe 5’-/56-FAM/ATGTCTGCA/ZEN/AGCACCATGGCTAAGGT/-3’. Finally, the rat 
RPS18 cDNA was amplified using the following set of primers and probe: sense 5’-
AGGACCTGGAGCGGCTGAAGAAA-3’, antisense 5’-TTCTTCTTGGACACACCCACAGTACG-3’ 
and probe 5’-/FAM/AGCCCATAG/ZEN/AGGGCTGCGCCACTTT-3’. The qPCR was realized 
in the Mx3000P thermocycle from Stratagene. The cycle conditions utilized for the 
reactions were: initial denaturation step at 95°C for 20 s, 40 repeated cycles composed 
of annealing at 60°C for 20 s and extension at 72°C for 1 s. All reactions were 
performed in triplicate. Serial dilutions were used to construct a standard curve and 
the quantity of cDNA amplified was calculated from this standard curve and the Ct 
value. The obtained values were normalized with the internal control gene. 
3.9. Cell proliferation 
3.9.1. Study of cell proliferation with 3H – Thymidine 
The 3H – Thymidine incorporation assay was used to measure cell proliferation. The 3H- 
Thymidine is a radioactive nucleoside that is incorporated in the DNA, during DNA 
synthesis, when mitotic cell division occurs. Cell division is subsequently estimated by 
the measurement of DNA radioactivity with a scintillation beta-counter. Consequently, 
the incorporation of 3H – Thymidine measures the synthesis of DNA and provides an 
approximate measurement of cell proliferation [153]. 
The cells were seeded in DME/F12 Base Medium, 10% FCS, 100 IU/mL penicillin and 
100 μg/mL streptomycin enriched with 1,2mM Ca2+, in 24 multiwell plates with 50% 
confluency and incubated overnight at 37°C and 5% CO2. After 24 hours, the cell 
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culture media was changed by DME/F12 BASE MEDIUM with 0,1% FCS, 100 IU/mL 
penicillin and 100 μg/mL streptomycin enriched with the appropriated concentrations 
of CaCl2 (0,1mM Ca
2+, 1,2mM Ca2+ and 3mM Ca2+) and were maintained in these media 
for 72 hours. Subsequently the cell culture media was replaced by DME/F12 BASE 
MEDIUM with 10% FCS, 100 IU/mL penicillin and 100 μg/mL streptomycin enriched 
with the appropriated concentrations of CaCl2 (0,1mM Ca
2+, 1,2mM Ca2+ and 3mM 
Ca2+) and the cells were incubated overnight at 37°C and 5% CO2. After 12 hours of 
incubation, the cell culture media was changed by DME/F12 BASE MEDIUM with 10% 
FCS, 0,2% 3H-thymidine (74KBq/ml) (Perkin Elmer, Boston, MA, USA), 100 IU/mL 
penicillin and 100 μg/mL streptomycin enriched with the appropriated concentrations 
of CaCl2 (0,1mM Ca
2+, 1,2mM Ca2+ and 3mM Ca2+) and incubated for 6 hours at 37°C 
and 5% CO2. Then, cell culture media was removed, the cells were washed twice with 
DPBS and treated with 5% trichloroacetic acid for 5 minutes. Subsequently, the cells 
were washed twice with deionized water (Milli Q) and incubated overnight with 500µl 
of sodium hydroxide solution 1N. Finally, the cells were recovered in appropriated 
vials, scintillation liquid was added to the cells and radioactivity was measured in a 
scintillation beta-counter 24 hours after. 
3.9.2. Study of cell proliferation with growth curves 
The growth of a cell population has exponential kinetics. If the graphic representation 
of the growth of a cell population is performed using LognºCells instead of the cell 
number, the graphic is composed by three growth phases: the lag phase, the log phase 
or exponential phase and the stationary or plateau phase. The lag phase is the 
immediate time that follows subculture and reseeding, where cell growth is minimal or 
absent. It is a period of adaptation for the cell, during which the cell attaches to the 
growth plate and synthesises elements of the cell structure lost during trypsinization. 
The exponential phase consists in the longest and main phase of all the growth phases, 
during which the cell growth is constant. The exponential phase occurs immediately 
after the lag phase and ends when cell confluency is achieved. The seeding density, the 
growth rate of the cells and the cell density that inhibits cell proliferation are the 
factors that influence the length of the exponential phase. Since that in the 
exponential phase the cell growth is uniform and the cells are viable, it is the best 
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phase of the cell growth to study cell proliferation. The plateau phase is the final phase 
in the cell growth and represents the phase in which cells are in confluency and cell 
proliferation has ceased completely or almost completely due to the high density of 
cells, the growth barrier of contact inhibition, the lack of available growth nutrients 
and the accumulation of toxins in the culture.  The concepts of generation time and 
population doubling time are important for the characterization of the cell growth 
cycle of a cell line. The generation time is the time period between two consecutive 
cell replications; more precisely it consists in the time measured since one point in the 
cell cycle achieves the same point in the cell cycle, after one cell replication. The 
population doubling time is the time necessary for the culture to increase two-fold in 
the exponential phase. The study of cell proliferation of a given cell line should be 
performed based only in the exponential phase of growth since the lag phase and the 
plateau phase are not adequate to the study of cell proliferation. In order to simplify 
the interpretation of a growth curve, the logarithms of the cell number values and the 
time can be used to construct the growth curves. The subsequent calculations are 
performed assuming that all the cells of a cell population are dividing and that cell 
division takes a similar time between all the cells [153]rmocalcemia (1,2mM Ca2+) and 
hypercalcemia (3mM Ca2+) in the proliferation rate of the stably transfected cell clones 
was evaluated with growth curves. The cells were seeded in 100mm cell culture dishes 
with a density of 6x103 cells per plate in GM and incubated overnight at 37°C and 5% 
CO2. After 24h the medium was replaced by DME/F12 Base Medium (Sigma, St. Louis, 
MO, USA), 10% FCS (Sigma, St. Louis, MO, USA), 100 IU/mL penicillin and 100 μg/mL 
streptomycin (Lonza, Verviers, Belgium) enriched with the appropriated 
concentrations of CaCl2 (0,12mM Ca
2+; 1,2mM Ca2+ or 3mM Ca2+). The cell culture 
media was refreshed every 3-4 days. The cells were counted directly from the growth 
plates, in an Axiovert 200 M inverted microscope (Zeiss, Oberkochen, Germany), in the 
field of the microscope camera, in phase contrast with a magnification of 10x. Each cell 
culture plate was placed in a petri dish lid, which was marked with 28 positions evenly 
distributed on the surface of the petri dish lid. The cell culture plate and the petri dish 
lid, were then placed together on the lens of the microscope at position number 1 of 
the petri dish lid and the cells presented at position number 1 were counted. 
Subsequently, the cell culture plate and the petri dish were moved together along the 
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lens of the microscope for the position number 2 of the petri dish lid and the cells 
present at position number 2 were counted. The cell counting proceeded in a similar 
fashion for the 28 positions marked in the petri dish lid. Every experiment was 
conducted in triplicate.  
 
 
Figure 3. Graphic representing the growth phases of a cell population 
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Figure 4.  Schematic image of a petri dish lid marked with 28 positions evenly distributed. 
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3.10. Immunocytochemistry 
The localisation of the intracellular CaSR and PTH proteins were evaluated by 
immunofluorescence staining with primary antibodies anti-CaSR and anti-PTH. In 
addition, the localisation of the CaSR in the plasmatic membrane of the cell surface 
was also studied by immunofluorescence staining with primary antibodies anti-CaSR. 
The nuclei were counterstained with TOTO-3. The cells were seeded in 24 multiwell 
plates in GM with a cell seeding density of 2 x 103 cells per well and incubated 
overnight at 37°C and 5% CO2. After 24 hours, the medium was changed by DME/F12 
BASE MEDIUM with 0,1% FCS, 100 IU/mL penicillin and 100 μg/mL streptomycin 
enriched with the appropriated concentrations of CaCl2 (0,1mM Ca
2+, 1,2mM Ca2+ and 
3mM Ca2+) and cells were growth in these medium for 72 hours. Subsequently, the 
cells were fixed in 4% paraformaldehyde (J.T. Barker, Deventer, Holland) in DPBS for 15 
minutes at room temperature (RT) and permeabilized in 0.5% Triton X-100 (Merck, 
Darmstadt, Germany) in DPBS for 10 minutes at RT. The permeabilization step was 
absent for the study of CaSR localisation in the cell surface. Non-specific binding sites 
were blocked with 2% bovine serum albumin (BSA) (Sigma, St. Louis, MO, USA) in DPBS 
for 30 min at RT. Cells were stained for CaSR using an anti-CaSR mouse monoclonal 
IgG2a, 5C10, ADD, primary antibody (Thermo Scientific, Rockford, IL, USA), dilution 
1:100 in 2% BSA/DPBS incubated overnight at 4ºC in a humidified chamber and a 
Alexa-Fluor 488 anti-rabbit IgG (H+L) donkey host secondary antibody (Eugene, OR, 
USA), dilution 1:50 in 2% BSA/DPBS for 60 min in the dark at RT in humidified chamber. 
Cells were stained for PTH using an anti-PTH rabbit polyclonal IgG, ab14169 primary 
antibody (Abcam, Cambridge, UK), dilution 1:200 in 2% BSA/DPBS incubated overnight 
at 4ºC in a humidified chamber and a FITC conjugated anti-rabbit IgG (H+L) mouse host 
secondary antibody (Invitrogen, CA, USA), dilution 1:200 in 2% BSA/DPBS for 60 min in 
the dark at RT in humidified chamber. Cell nuclei were counterstained with 5 μM 
TOTO-3 iodide (Invitrogen, CA, USA) for 30 min in the dark at RT in a humidified 
chamber after RNA digestion with 500 μg/ml RNase I-A (Sigma, ST. Louis, MO, USA) for 
30 min at 37°C. Samples were rinsed three times with DPBS and 2 times with 2% 
BSA/DPBS between each step. Cells were observed in Laser Scanner Confocal 
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Microscopy (LSCM) using a LSM510META Microscope equipped with 
Ar/ML458/477/488/514, HeNe543, HeNe633 Laser Lines. 
3.11. Determination of PTH modulation in response to Ca2+0 
The analysis of PTH intracellular levels and PTH secretion was performed with the rat 
Intact PTH ELISA kit (Immunotopics, San Clemente, CA, USA), according to the 
manufacturer’s instructions.  
The cells were treated separately to obtain separate samples to study intracellular PTH 
levels and PTH secretion.  
In order to obtain the samples to analyse intracellular PTH levels, the cells were 
seeded in 100 mm dishes, in GM, with a cell seeding density of 2 x 106 cells per plate 
and incubated overnight at 37°C and 5% CO2. The following day the media was 
changed by DME/F-12 BASE MEDIUM with 10% FCS, 100 IU/mL penicillin and 100
μg/mL streptomycin enriched with the appropriated concentrations of CaCl2 (0,12mM 
Ca2+; 1,2mM Ca2+ or 3mM Ca2+). The cells were incubated in these media for 72h. 
Subsequently, the media was removed from the plates, the cells were washed one 
time with cold PBS, detached with Trypsin (Sigma, St. Louis, MO, USA), recovered in 
DME/F-12 BASE MEDIUM with 10% FCS, 100 IU/mL penicillin and 100 μg/mL 
streptomycin enriched with the appropriated concentrations of CaCl2 in 15 ml 
centrifuge tubes and centrifuged at 5000 g for 5 minutes at room temperature. The 
supernatant was removed from the tubes, 1 ml of DME/F-12 BASE MEDIUM with 10% 
FCS, 100 IU/mL penicillin and 100 μg/mL streptomycin enriched with the appropriated 
concentrations of CaCl2 was added to each tube, the cell pellet was dissolved in the 
media, transferred to clean 1,5 ml Eppendorf tubes and centrifuged at 5000 g for 5 
minutes at 4ºC. The supernatant was removed, cell pellet was dissolved in 150µl of 
DME/F-12 BASE MEDIUM with 10% FCS, 100 IU/mL penicillin and 100 μg/mL 
streptomycin and stored at -20ºC until the assay.  
The samples to be used in the PTH secretion assay were obtained by seeding the cells 
in 6 multiwell plates, in GM, with a cell density of 2x 105 cells per well and growth at 
37°C and 5% CO2 until 80% confluency. The medium was then removed and changed 
by 2ml of DME/F-12 BASE MEDIUM with 10% FCS, 100 IU/mL penicillin and 100 μg/mL 
streptomycin enriched with the appropriated concentrations of CaCl2 (0,12mM Ca
2+; 
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1,2mM Ca2+ or 3mM Ca2+). The cells were incubated at 37°C and 5% CO2 in this 
medium for 1h. Subsequently, the media was removed from the plates, collected in 
clean 2ml Eppendorf tubes and stored at -80°C until the assay. The cells were washed 
once with cold PBS, detached with Trypsin and suspended in GM. Finally, cell number 
was counted in a bürker chamber. 
3.12. Statistical analysis 
The statistical analysis for the growth curves was performed by the linear regression of 
each growth curve, the calculation of the coefficient of determination (R2), the linearity 
test and the population doubling time for each linear regression. The linear regression 
of each growth curve was performed by placing the values of log10nºcells as a function 
of time (hours). The statistical significant differences between each stimulus and 
control were determined with the parallelism test for each linear regression. The 
statistical analysis for the experiments of cell proliferation with 3H-thymidine and study 
of PTH modulation by Ca2+0 were performed with the T-Student Test.  
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4. Results 
4.1. Construction of the CaSR pcDNA3.1/Zeo(+) 
4.1.1. Digestion of the CaSR p-sport 1 bacterial plasmid vector with 
restriction enzymes 
 
 
 
Figure 5. Electrophoresis on an agarose gel (0,8%). Digestion of the CaSR p-sport 1 
bacterial expression vector with the restriction enzymes NotI/KpnI/PvuI. 
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4.1.2. Digestion of the pcDNA3.1/Zeo(+) plasmid expression vector with 
restriction enzymes 
 
 
Figure 6. Electrophoresis on an agarose gel (0,8%). Digestion of the pcDNA3.1/Zeo(+) 
plasmid expression vector with the restriction enzymes NotI/KpnI. 
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4.1.3. PCR to the CaSR gene in the results of the ligation reaction to the 
construction of the CaSR pcDNA3.1/Zeo(+) plasmid vector 
 
Figure 7. Electrophoresis on an agarose gel (2%). PCR to the CaSR gene in ligation reactions.  
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4.2. Digestion of the CaSR pcDNA3.1/Zeo(+) and PTH pcDNA3.1/Zeo(+) 
plasmid expression vectors with restriction enzymes 
 
 
Figure 8. Electrophoresis on an agarose gel (0,8%). Digestion of the CaSR pcDNA3.1/Zeo(+) and PTH 
pcDNA3.1/Zeo(+) plasmid expression vectors with the restriction enzymes NotI/KpnI and HindIII/EcoRI, 
respectively. 
4.3. Sequence of the CaSR mRNA inserted in the pcDNA3.1/Zeo(+) 
CaSR mRNA, Rattus norvergicus (Norway rat) (4113bp) 
1   cgggactctc caggccggct caggcaccgg actgtaggtg tatttggagg gatttggagg       
61  ctggagaccc caggaagcac gcaggcggga gcaggcaagg ggcggagccc cgggcccggc      
121 caaggtggcc gtcagagggt ctgcggggag gcagtagctt gacccaaggc gaccagggaa      
181 cttcagacgg tagcacgcca ctcaaacaaa ttaacttgac atcgcaagct gggcgggctg      
241 gtacgacatc ctgacttcag catccagctg ttcctgggca gacagagggc caacaggtgt      
301 tcctgtggaa gaagccagga caaggactcc agaaaacatc tcgggcagcc tctacatgat      
361 gtcacttctc aggactcgag gaccagccac cctacacctc tactacagag aaggcagaaa      
421 tggagaccca aaggccatca ctcctgctct gtcactaacc actctgtaat catgtctccc      
481 caccagaagg tgtgaaccgc accagggccg tggagttctc gggctcccaa tccactgaca      
541 cctttacctg tcccctgaag agaaggcaac gctatggcat cgtacagctg ctgtttggcc      
601 ctattggctc ttgcctggca ctcctctgcc tatgggcctg accagcgagc ccaaaagaag      
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661 ggggacatta tcctaggagg tctctttcct atccattttg gagtagcagc caaagatcaa      
721 gatctgaagt caagaccaga gtctgtggag tgcattaggt ataacttccg tggattccga      
781 tggttacaag ccatgatatt cgccatagag gagataaaca gcagcccctc ccttcttccc      
841 aacatgacac tgggatatag gatatttgac acctgtaaca ccgtctccaa ggcgctggaa      
901 gccaccttga gttttgttgc ccagaacaaa atcgattctt tgaacctgga cgagttctgc      
961 aactgctctg agcacatccc ttcgaccatt gccgtggtgg gagccaccgg ctccggtgtc     
1021 tccacggcgg tagccaacct gctgggactt ttctacatcc cccaggtgag ctacgcctcc     
1081 tccagcaggc tcctcagcaa taagaaccag tacaaatcct tcctccgcac cattcccaat     
1141 gacgaacacc aggcaaccgc gatggccgac atcatcgagt acttccgctg gaactgggtg     
1201 ggcacaattg cagctgatga cgactatggc agacctggca ttgagaagtt ccgagaggaa     
1261 gccgaagaga gggatatctg cattgatttt agcgagctca tctcccagta ctctgacgag     
1321 gaagagatcc agcaggtggt cgaagtgatc caaaactcta cggccaaggt cattgtcgtt     
1381 ttctccagcg gcccggacct agaacctctc atcaaggaga ttgtgcggcg taacatcaca     
1441 ggcaggatct ggctggctag cgaggcctgg gccagttcct cgctgattgc tatgcctgag     
1501 tatttccatg tagtcggggg caccattggg ttcggtctga aggctgggca gattccaggc     
1561 ttcagagaat tcctacagaa agttcatcct aggaagtctg tccacaatgg ttttgccaaa     
1621 gagttttggg aagaaacttt taattgccac ctccaagaag gcgcaaaagg acctttacct     
1681 gtggacacct tcgtgagaag tcacgaagaa ggtggcaaca ggttactcaa tagctctact     
1741 gccttccgac ccctctgcac aggggatgag aacatcaaca gtgtggagac cccttacatg     
1801 gattacgaac atttacggat atcctacaat gtgtacttag ccgtctactc cattgcgcat     
1861 gccctacaag atatatacac ctgcttaccc ggaagagggc ttttcaccaa cgggtcctgt     
1921 gcagacatca agaaggttga ggcctggcag gtcttgaagc acctacggca cctgaacttc     
1981 accaacaaca tgggggagca ggtgaccttc gatgagtgtg gtgatctggt ggggaactat     
2041 tctatcatca actggcacct ctccccagag gacggctcca ttgtgttcaa ggaagttggg     
2101 tactacaatg tgtatgccaa gaagggagaa agactcttca tcaatgagga gaagatcttg     
2161 tggagtgggt tctccagaga ggtgcctttc tccaattgca gccgggactg tcaggcaggg     
2221 accaggaagg ggatcatcga gggagagccc acctgctgct ttgagtgtgt ggagtgtcct     
2281 gatggagagt acagtggaga gacagatgcg agtgcctgtg acaagtgccc ggatgacttc     
2341 tggtccaatg agaaccacac ttcttgcatt gccaaggaga ttgagtttct ggcgtggacc     
2401 gagccctttg gaatcgctct cactctcttt gcggtgctgg gcattttcct gaccgccttt     
2461 gtgctgggtg tcttcatcaa gttccgaaac acacctatcg tcaaggccac caaccgagaa     
2521 ctgtcctacc tcctgctctt ctccctactc tgctgcttct ccagctcctt gttcttcatt     
2581 ggggagcccc aggactggac gtgccgcctg cgacagcctg ctttcggcat cagctttgtg     
2641 ctctgtatct cgtgcatctt ggtgaagacc aatcgcgtcc tcctggtatt tgaagccaag     
2701 atacccacca gcttccaccg gaagtggtgg gggctcaacc tgcagttcct gctggttttc     
2761 ctctgcacct tcatgcagat cctcatctgc atcatctggc tctacacggc gcccccctct     
2821 agctaccgca accatgagct ggaagacgaa atcatcttca tcacgtgcca tgagggctca     
2881 ctcatggcac ttggctccct gatcggctat acctgcctgc tggctgccat ctgcttcttc     
2941 tttgccttca agtccaggaa gttaccagag aacttcaacg aagccaagtt cattaccttc     
3001 agcatgctca tcttcttcat cgtctggatc tccttcattc cagcctatgc cagcacctac     
3061 ggcaagtttg tctctgccgt agaggtgatc gccattttgg cagccagctt tggcttacta     
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3121 gcctgcatct tcttcaacaa ggtctacatt atcctcttca agccttcccg gaacaccatt     
3181 gaggaagtcc gctccagcac cgcagcacat gctttcaaag tagcagcccg cgccactcta     
3241 cgccgtccca acatctcccg gaagcggtcc agcagccttg gaggctccac cggctccatt     
3301 ccctcctcct ccatcagcag caaaagcaac agcgaagacc ggttcccgca gccagagagg     
3361 cagaagcaac agcaaccgct gtccctgacc cagcaagaac agcagcagca gcccctgacc     
3421 ctccacccac agcaacagca gcagccacag cagccgagat gcaaacagaa ggtcatcttc     
3481 ggcagtggta cggtcacctt ctctctgagt tttgacgagc ctcagaagaa tgccatggcc     
3541 cacaggaact ccatgcgtca gaactccctg gaggcccaga ggagcaacga caccttgggc     
3601 agacaccagg ccctgcttcc cctacagtgt gcagatgcgg actcagaaat gaccattcag     
3661 gaaacgggcc tgcaagggcc catggtgggg gaccaccagc cagaaatgga aagctcagat     
3721 gaaatgtccc cagcgctggt catgtccacc tctcggagct tcgtcattag tggtggaggt     
3781 agctctgtga cggaaaacgt attacactcc taatggaggg aaaggctatc cagttgagag     
3841 gtttttctta gagccctgag caaaaggatg ggtccttcct ttcttcccag gaagccaggg     
3901 agagtaggta cgtcaaagcc tgtactcagt tgcactgctt tgaatgacag tgaactgact     
3961 ggtgtgctct ttagagttaa aagaagagcc atgttttggg gtcgttttcc agagctcagt     
4021 atcacacctg ggtttgctga agtcttttcc tctgctctat ccaccatcag ttcagacgaa     
4081 agcaaggctc taagctaccc atctgcttcc ctc aaaaaaaaaaaaaaaaa 
4.4. Sequence of the PTH mRNA inserted in the pcDNA3.1/Zeo(+) plasmid 
expression vector 
PTH mRNA, Rattus norvergicus (Norway rat) (701bp) 
1   ctgcatatga aactcaggct tgaagaactg cagtccagtt catcagctgt ctggcttact 
61  ccagcttaat acagggtcac tcctgaagga tcctctctga gagtcattgt atgtgaagat 
121 gatgtctgca agcaccatgg ctaaggtgat gatcctcatg ctggcagttt gtctccttac 
181 ccaggcagat gggaaacccg ttaagaagag agctgtcagt gaaatacagc ttatgcacaa 
241 cctgggcaaa cacctggcct ctgtggagag gatgcaatgg ctgagaaaaa agctgcaaga 
301 tgtacacaat tttgttagtc ttggagtcca aatggctgcc agagaaggca gttaccagag 
361 gcccaccaag aaggaggaaa atgtccttgt tgatggcaat tcaaaaagtc ttggcgaggg 
421 ggacaaagct gatgtggatg tattagttaa ggctaaatct cagtaaatgc tgacgtattc 
481 tagaccgtgc tgagcaataa catatgctgc tatcctttca agctccacga agatcaccaa 
541 gtgctaattc ttctactgta ataaaagttt gaaatttgat tccacttttg ctcatttaag 
601 gtctcttcca atgattccat ttcaatatat tcttcttttt aaagtattac acatttccac 
661 ttctctcctt aaatataaat aaagtttaat gatcatgaac caaa 
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4.5. Transient Transfections 
4.5.1. Optimization of transient transfections 
Transient transfection was first performed in order to verify if the plasmid expression 
vectors CaSR pcDNA3.1/Zeo(+) and PTH pcDNA3.1/Zeo(+) constructed were functional 
and also to verify if PTH-C1 cells could be transfected. The plasmid expression vector 
pcDNA3.1/Zeo(+) empty was used as a control in the transient transfections. The 
recombinant plasmid vector CaSR pcDNA3.1/Zeo(+) was the first to be tested. 
Transient transfection was initially tested with different quantities of Attractene 
transfection reagent and plasmid DNA in order to determine the optimal ratio of 
plasmid DNA and Attractene transfection reagent to be used in transient and stable 
transfections. Consequently three quantities of CaSR pcDNA3.1/Zeo(+) plasmid DNA 
(200ng, 400ng and 600ng) were tested in simultaneous with three different volumes of 
Attractene transfection reagent (0,75µl, 1,5µl and 2,25µl), in the PTH-C1 cells. The cells 
were transiently transfected according to the tranfection protocol of the Attractene 
Tranfection Reagent from Qiagen and were analysed by PCR and qPCR 24h after 
transient transfection.  
The qualitative analysis of CaSR mRNA expression level of the PTH-C1 cells transiently 
transfected with the pcDNA3.1/Zeo(+) with different ratios of plasmid DNA and 
Attractene transfection reagent, by PCR reaction, were consistent with the transient 
integration of the CaSR gene in the genome of the PTH-C1 cells. Furthermore, the 
quantitative analysis of CaSR mRNA expression level, performed by qPCR in the cells 
transiently transfected with the CaSR gene, revealed an increase in CaSR mRNA levels 
when increased ratios of plasmid DNA and Attractene transfection reagent were used. 
The results obtained either with the PCR reaction and the qPCR indicate that the 
expression levels of CaSR mRNA are increased in the cells transiently transfected with 
the CaSR pcDNA3.1/Zeo(+) plasmid expression vector, whereas the results show that 
the CaSR gene is expressed at a very low level in the PTH-C1 cells transiently 
transfected with the empty pcDNA3.1/Zeo(+) plasmid expression vector. The optimal 
ratio of plasmid DNA and Attractene transfection reagent chosen to the subsequent 
transient and stable transfections was 200ng of plasmid DNA and 0,75µl of Attractene 
reagent, which is the lowest ratio of plasmid DNA and Attractene transfection reagent  
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tested. In spite of the higher expression level of CaSR mRNA obtained with the higher 
ratio of plasmid DNA and transfection reagent, the lowest ratio of plasmid DNA and 
transfection reagent was chosen to be used in further transfections because it yield 
also a reasonable level of expression of CaSR mRNA and decreased the cytotoxicity to 
the cells, at the same time. 
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Figure 9. PCR results for the CaSR gene in PTH-C1 cells transiently transfected with different ratios of 
CaSR pcDNA3.1/Zeo(+) plasmid DNA and Attractene transfection reagent. The plasmid expression vector 
pcDNA3.1/Zeo(+) empty was used as a negative control in the transient transfection. 
Figure 10. Quantitative expression levels of the CaSR mRNA in the PTH-C1 cells transiently transfected 
with the plasmid CaSR pcDNA3.1/Zeo(+).The plasmid expression vector pcDNA3.1/Zeo(+) empty was 
used as a negative control in the transient transfection. 
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4.5.2. Transient transfections with CaSR pcDNA3.1/Zeo(+) and PTH 
pcDNA3.1/Zeo(+) 
Several transient transfections were performed in the PTH-C1 cells once the optimal 
ratio of plasmid DNA and reagent transfection were optimized (200ng of Plasmid DNA 
and 0,75µl of Attractene transfection reagent).  
With the aim of establishing in the future PTH-C1 clones stably expressing the CaSR 
and/or the PTH gene(s), the CaSR pcDNA3.1/Zeo(+) and PTH pcDNA3.1/Zeo(+) plasmid 
expression vectors were first transiently transfected into the PTH-C1 cells, alone or in 
simultaneous, in conditions of 1,2mM Ca2+.   
The results of the transient transfections with the two recombinant plasmid vectors, 
CaSR pcDNA3.1/Zeo(+) and PTH pcDNA3.1/Zeo(+) were evaluated by PCR reaction. The 
PCR for the CaSR and PTH genes from the transiently transfected PTH-C1 cells showed 
the appropriated bands for the CaSR in the separate populations of cells transiently 
transfected with either the CaSR pcDNA3.1/Zeo(+) plasmid alone or both CaSR 
pcDNA3.1/Zeo(+) and PTH pcDNA3.1/Zeo(+) plasmids. Similarly, the PCR to the PTH 
gene from PTH-C1 cells transiently transfected either with the PTH pcDNA3.1/Zeo(+) 
plasmid alone or both CaSR pcDNA3.1/Zeo(+) and PTH pcDNA3.1/Zeo(+) plasmids 
presented the appropriated bands for the PTH gene. In contrast, cells transiently 
transfected with the pcDNA3.1/Zeo(+) empty plasmid showed any amplification of the 
CaSR or PTH genes.  
These results indicate that the transient transfection was successful and demonstrate 
that PTH-C1 cells can transiently express the CaSR and PTH genes alone or in 
simultaneous, when are transfected only with one gene or with both genes together. 
More importantly, the results showed that PTH-C1 cells are possibly able to be stably 
transfected.  
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Figure 11. PCR results for the CaSR and PTH genes in the PTH-C1 cells transiently transfected with the 
CaSR pcDNA3.1/Zeo(+) and/or the PTH pcDNA3.1/Zeo(+) plasmid expression vectors. The plasmid 
expression vector pcDNA3.1/Zeo(+) empty was used as a negative control in the transient transfection. 
4.6. Stable Transfection 
In order to obtain PTH-C1 cell clones stably expressing the CaSR or the PTH genes, the 
PTH-C1 cells were stably transfected separately with CaSR pcDNA3.1/Zeo(+) and PTH 
pcDNA3.1/Zeo(+) plasmid expression vectors. In addition, with the aim of obtaining 
PTH-C1 clones stably expressing both CaSR and PTH genes, the PTH-C1 cells were 
stably transfected in simultaneous with the plasmid expression vectors CaSR 
pcDNA3.1/Zeo(+) and PTH pcDNA3.1/Zeo(+). The empty pcDNA3.1/Zeo(+) plasmid 
expression vector was used as a negative control in the stable transfections. 
4.6.1. Determination of the concentration of Zeocin able to kill PTH-C1 
cells 
In order to select the cells stably expressing the CaSR and/or PTH genes, it was first 
determined the sensitivity of the PTH-C1 cells to the antibiotic Zeocin, since the 
plasmid expression vector pcDNA3.1/Zeo(+) contains a Zeocin selectable marker. The 
antibiotic Zeocin belongs to the bleomycin/phleomycin family and is toxic against 
mammalian cells, bacteria and fungi. Zeocin is formed by phleomycin D1, a copper-
chelated glycopeptide isolated from Streptomyces verticillus. The copper-chelated 
form of Zeocin is inactive, however, inside the cell the copper is reduced from Cu2+ to 
Cu+ and the Cu+ is removed, leading to the activation of Zeocin, which became able to 
bind and cleave DNA, resulting in cell death. To determine the optimal concentration 
of Zeocin to use in the stable transfection, PTH-C1 cells were treated with different 
concentrations of Zeocin for 20 days (50µg/ml, 100µg/ml, 250µg/ml,  
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500µg/ml and 1000µg/ml). Abnormal cell shape was observed in the PTH-C1 cells 
treated with Zeocin concentrations of 50µg/ml, 100µg/ml and 250µg/ml, with more 
visible cell shape abnormalities at the concentration of 250µg/ml of Zeocin, however, 
these three lowest concentrations of Zeocin were not able to kill completely the PTH-
C1 cells. In contrast, the Zeocin concentrations of 500µg/ml and 1000µg/ml completely 
killed the PTH-C1 cells, which were completely dead and detached from the culture 
plates before the end of the experiment.   
Furthermore, at the end of the experiment the cells were stained with acridine orange 
and ethidium bromide, in order to better evidence dead and live cells. Acridine Orange 
is a nucleic acid dye, able to permeate the plasmatic membrane of live cells and to 
bind both DNA and RNA by intercalating or electrostatic attractions. Ethidium bromide 
is not able to permeate the membrane of live cells, however, it is able to stain 
apoptotic cells or cells in that are almost completely dead, since the plasma membrane 
is more permeable in these unhealthy cells. Acridine Orange stains live cells of green 
and Ethidium bromide stains dead cells of red. The cells treated with 500µg/ml and 
1000µg/ml of Zeocin have fully detached from the cell plate before the end of the 
experiment, making impossible to perform the vital coloration with Acridine Orange 
and Ethidium Bromide on them. The optimal concentration of Zeocin chosen to 
perform the stable transfection was 500µg/ml, since it was the lowest concentration of 
Zeocin able to completely kill the PTH-C1 cells during the time of the experiment. 
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Figure 12. Determination of PTH-C1 cells sensitivity to the antibiotic Zeocin. Results for PTH-C1 cells 
stained with acridine orange and ethidium bromide. Viable cells are stained in green by acridine orange 
and dead cells are colored in red by ethidium bromide. PTH-C1 cells treated with 50µg/ml of Zeocin (A); 
PTH-C1 cells treated with 100µg/ml of Zeocin (B); PTH-C1 cells treated with 250µg/ml of Zeocin (C) and 
PTH-C1 cells not treated with Zeocin, negative control of the experiment (D). Images acquired in a Laser 
Scanning Confocal Microscope (LSCM), with an amplification of 10x.  
4.6.2. Establishment of heterogeneous populations of cells stably 
transfected with CaSR and PTH genes 
The stable transfection of the PTH-C1 cells with CaSR pcDNA3.1/Zeo(+) and PTH 
pcDNA3.1/Zeo(+) plasmid expression vectors, separately, as well as the stably 
transfection of the PTH-C1 cells with both CaSR pcDNA3.1/Zeo(+) and PTH 
pcDNA3.1/Zeo(+) plasmid expression vectors in simultaneous, originated first 
heterogeneous populations of cells stably transfected with the CaSR gene, the PTH 
gene and both CaSR and PTH genes together. The stable expression of the CaSR and 
PTH genes in the three heterogeneous populations of cells was qualitatively evaluated 
A B 
C D 
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by PCR reaction. The results of the PCR reaction showed the adequate bands 
corresponding to the CaSR and PTH genes, confirming that the stable transfection has 
been successful. The results of the PCR reaction showed the establishment of four 
different populations of heterogeneous PTH-C1 cells: one first heterogeneous 
population of cells stably transfected with the CaSR gene, a second heterogeneous 
population of cells stably transfected with the PTH gene, a third heterogeneous 
population of cells stably transfected with both CaSR and PTH genes together and a 
forth heterogeneous population of cells transfected with the empy pcDNA3.1/Zeo(+) 
plasmid expression vector. 
 
 
Figure 13. Establishment of heterogeneous populations of PTH-C1 cells with stable expression of the 
CaSR and/or PTH genes, as well as stable expression of the empty pcDNA3.1/Zeo(+) plasmid 
expression vector. PCR results for the CaSR and PTH genes in the heterogeneous populations of PTH-C1 
cells stably transfected with the CaSR pcDNA3.1/Zeo(+) and/or the PTH pcDNA3.1/Zeo(+) plasmid 
expression vectors. The plasmid expression vector pcDNA3.1/Zeo(+) empty was used as a negative 
control in the stable transfections. 
4.6.3. Cell Cloning 
The three heterogeneous populations of PTH-C1 cells stably transfected with the CaSR 
gene, the PTH gene and both CaSR and PTH genes together were subsequently cloned 
by the limiting dilution method, with the goal of establish single cell clones stably 
expressing individually the CaSR gene, the PTH gene and both CaSR and PTH genes 
together. In order to verify which clones had successfully incorporate the CaSR gene, 
the PTH gene and both CaSR and PTH genes together in the genome of the PTH-C1 
cells, the several obtained clones were analysed by PCR reaction to evaluate 
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qualitatively the expression level of the CaSR and PTH genes. The results of the PCR 
analysis revealed the existence of two single clones stably expressing the CaSR gene, 
nine single clones stably expressing the PTH gene and four single clones stably 
expressing both the CaSR and PTH genes, confirming the success of the cloning. 
 
Figure 14. Establishment of single PTH-C1 cell clones with stable expression of the CaSR gene. PCR 
results for the CaSR gene in the two CaSR positive clones obtained with the stable transfection. 
 
 
Figure 15. Establishment of single PTH-C1 cell clones with stable expression of the PTH gene. PCR 
results for the PTH gene in the nine PTH positive clones obtained with the stable transfection. 
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Figure 16. Establishment of single PTH-C1 cell clones with stable expression of both CaSR and PTH 
genes. PCR results for the CaSR gene (A) and the PTH gene (B) in the four double CaSR and PTH positive 
clones obtained with the stable transfection. 
4.7. Sequencing of the isolated clones 
All the stable PTH-C1 clones obtained were sequenced for the CaSR and PTH full lenght 
genes. The homology of cDNA sequences of CaSR and PTH genes obtained was 
matched with the sequences reported in GENEBANK with Blast and revealed 100% of 
homology.  
4.8. Cell Proliferation 
4.8.1. Study of cell proliferation with growth curves 
The cell proliferation rates of the PTH-C1 clones stably transfected with the CaSR gene, 
the PTH gene (only one clone studied) and with both CaSR and PTH genes, as well as 
the PTH-C1 cells stably transfected with the empty pcDNA3.1/Zeo(+) plasmid 
expression vector, were evaluated with growth curves. The clones and the cells 
transfected with the empty plasmid were growth in conditions of hypocalcemia 
(0,12mM Ca2+), normocalcemia (1,2mM Ca2+) and hypercalcemia (3mM Ca2+) and the 
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population doubling time was calculated for each growth curve correspondent to 
different CaCl2 stimulus in the growth media. The statistical analysis was performed 
first for each clone separately, considering the growth curve in normocalcemia has the 
control and the growth curves in hypocalcemia and hypercalcemia has the stimulus. A 
second statistical analysis was done to compare the growth curve of each stably 
transfected CaSR clones, stably transfected PTH clone and stably transfected double 
CaSR and PTH clones to the growth curve obtained for the PTH-C1 cells stably 
transfected with the empty pcDNA3.1/Zeo(+) plasmid expression vector. On this 
second statistical analysis the growth curves obtained for the diverse cell clones were 
considered has the stimulus and the growth curve obtained for the cells transfected 
with the empty plasmid was considered as the control.  
The cell population doubling times obtained for the two stable CaSR clones were: 33 
hours at hypocalcemia; 28,9 hours at normocalcemia and 33,4 hours at hypercalcemia 
for the clone B6 and 18,2 hours at hypocalcemia; 17 hours at normocalcemia and 17,7 
hours at hypercalcemia for the clone D12. However, no significant statistical 
differences were found in the population doubling times of the two CaSR clones 
growth in the different Ca2+0 concentrations. 
The clone stably transfected with the PTH gene (clone D12 PTH) presented a 
population doubling time of 16,5 hours at hypocalcemia, 16,4 hours at normocalcemia 
and 15 hours at hypercalcemia. As was expected no significant statistical differences 
were found between the cell population doubling times obtained at hypocalcemia, 
normocalcemia and hypercalcemia for the D12 PTH stably transfected clone.  
The four double clones, stably overexpressing both CaSR and PTH genes, showed the 
following cell population doubling times: 15,8 hours at hypocalcemia, 15,9 hours at 
normocalcemia and 16,8 hours at hypercalcemia for the clone B9; 21 hours at 
hypocalcemia, 21 hours at normocalcemia and 19,5 hours at hypercalcemia for the 
clone C8; 23,9 hours at hypocalcemia, 20,6 hours at normocalcemia and 24 hours at 
hypercalcemia for the clone D11 and, finally, 19,1 hours at hypocalcemia, 21 hours at 
normocalcemia and 17,1 hours at hypercalcemia for the clone G5. Similarly to the 
results obtained for the two clones stably overexpressing the CaSR gene, no significant 
statistical differences were found between the cell population doubling times obtained 
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at hypocalcemia, normocalcemia and hypercalcemia for the four clones stably 
transfected with both CaSR and PTH genes.  
The statistical analysis between the cells stably transfected with the empty 
pcDNA3.1/Zeo(+) plasmid expression vector and the two clones stably overexpressing 
the CaSR gene, the clone stably transfected with the PTH gene and the four clones 
stably overexpressing both CaSR and PTH genes was significant only for one of the 
CaSR stable clones, the clone B6. All the other clones did not present any significant 
statistical differences in the cell population doubling times for the cells growth in 
hypocalcemia, normocalcemia and hypercalcemia, when compared with the cell 
population doubling times of the cells transfected with the empty plasmid growth in 
different [Ca2+0]s. 
 
 
 
Figure 17. Growth Curves for the clone B6, stably overexpressing the CaSR gene, in hypocalcemia 
(0,12mM Ca
2+
), normocalcemia (1,2mM Ca
2+
) and hypercalcemia (3mM Ca
2+
). 
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Figure 18. Growth Curves for the clone D12, stably overexpressing the CaSR gene, in hypocalcemia 
(0,12mM Ca
2+
), normocalcemia (1,2mM Ca
2+
) and hypercalcemia (3mM Ca
2+
). 
 
 
 
Figure 19. Growth Curves for the clone B9, stably overexpressing both CaSR and PTH genes, in 
hypocalcemia (0,12mM Ca
2+
), normocalcemia (1,2mM Ca
2+
) and hypercalcemia (3mM Ca
2+
). 
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Figure 20. Growth Curves for the clone C8, stably overexpressing both CaSR and PTH genes, in 
hypocalcemia (0,12mM Ca
2+
), normocalcemia (1,2mM Ca
2+
) and hypercalcemia (3mM Ca
2+
). 
 
 
 
 
Figure 21. Growth Curves for the clone D11, stably overexpressing both CaSR and PTH genes, in 
hypocalcemia (0,12mM Ca
2+
), normocalcemia (1,2mM Ca
2+
) and hypercalcemia (3mM Ca
2+
). 
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Figure 22. Growth Curves for the clone G5, stably overexpressing both CaSR and PTH genes, in 
hypocalcemia (0,12mM Ca
2+
), normocalcemia (1,2mM Ca
2+
) and hypercalcemia (3mM Ca
2+
). 
 
 
 
 
Figure 23. Growth Curves for the clone D12, stably overexpressing the PTH gene, in hypocalcemia 
(0,12mM Ca
2+
), normocalcemia (1,2mM Ca
2+
) and hypercalcemia (3mM Ca
2+
). 
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Figure 24. Growth Curves for the cells stably transfected with the empty pcDNA3.1/Zeo(+) plasmid 
expression vector, in hypocalcemia (0,12mM Ca
2+
), normocalcemia (1,2mM Ca
2+
) and hypercalcemia 
(3mM Ca
2+
). 
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PTH gene and both CaSR and PTH genes together, in hypocalcemia (0,12mM Ca
2+
), normocalcemia 
(1,2mM Ca
2+
) and hypercalcemia (3mM Ca
2+
). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Graphic for all the population doubling times obtained for the cells stably transfected with 
the empty pcDNA3.1/Zeo(+) plasmid expression vector and the cell clones stably overexpressing the 
CaSR gene, the PTH gene and both CaSR and PTH genes together, in hypocalcemia (0,12mM Ca
2+
), 
normocalcemia (1,2mM Ca
2+
) and hypercalcemia (3mM Ca
2+
). 
4.8.2. Study of cell proliferation with 3H – Thymidine 
Cell proliferation was also measured with the 3H – Thymidine incorporation assay. The 
incorporation of 3H – Thymidine was assayed in the two clones stably expressing the 
CaSR gene, in two of the four clones stably expressing both CaSR and PTH genes and in 
the cells stably transfected with the empty pcDNA3.1/Zeo(+) plasmid expression 
vector, in order to study the rate of cell proliferation. The clones B6 and D12, stably 
transfected with the CaSR gene and the clone C8, stably expressing both CaSR and PTH 
genes, showed a decreased synthesis of DNA at higher Ca2+0 concentrations (3mM), 
when compared with lower Ca2+0 concentrations (0,1mM and 1,2mM). The clone B6 
showed a diminished synthesis of DNA from 0,1mM Ca2+ to 1,2mM Ca2+, with a 
statistical significance of ρ <0,05; a decreased DNA synthesis from 1,2mM Ca2+ to 3mM 
Ca2+, with a statistical significance of ρ<0,01 and a decrease in the DNA synthesis from 
0,1mM Ca2+ to 3mM Ca2+, with a statistical significance of ρ<0,01. The clone D12 
showed a statistical significant (ρ<0,01) decrease in the synthesis of DNA from 0,1mM 
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Ca2+ to 3mM Ca2+. Finally, the clone C8 showed a decrease in the synthesis of DNA 
from 0,1mM Ca2+ to 3mM Ca2+, with a statistical significance of ρ<0,01. The clone G5 
did not show any decrease in the DNA synthesis, independently from the Ca2+0 levels 
and, as was expected, the cells transfected with the empty plasmid did not present any 
decrease in the synthesis of DNA independently from the Ca2+0 levels, as well.  
 
 
Figure 27. Incorporation of 
3
H – Thymidine obtained for the two clones stably transfected with the CaSR 
gene (B6 and D12), for two clones (C8 and G5) from the four clones stably expressing both CaSR and PTH 
genes and for the cells stably transfected with the empty plasmid.  
4.9. Study of protein expression – Immunofluorescence staining for CaSR 
and PTH proteins 
In order to determine if the clones stably transfected with CaSR and/or PTH genes 
were able to express the CaSR and PTH genes at protein level, the obtained clones 
were stained in immunofluorescence with primary antibodies anti-CaSR and anti-PTH.  
The expression of the CaSR protein was evaluated both at intracellular level and at the 
cell surface level. The intracellular level of CaSR was accessed in permeabilized cells, 
whether the expression of the CaSR in the cell surface was studied in non-
permeabilized cells, in order to maintain almost intact the plasmatic membrane, so 
that the primary antibody anti-CaSR was only able to stain the proteins located in the 
cell surface.  
In addition, the protein expression level of CaSR and PTH genes were studied in 
hypocalcemia (0,1mM Ca2+), normocalcemia (1,2mM Ca2+) and hypercalcemia (3mM 
78 
 
Ca2+), with the aim of evaluate if CaSR and PTH pattern of protein expression were 
variable with changes in the Ca2+0 concentrations.   
The expression of CaSR protein was visible in all the clones stably transfected with the 
CaSR gene and in all the clones stably transfected with both CaSR and PTH genes. 
However, the level of expression of CaSR protein was not equal in all the clones, some 
of the clones appeared to have a higher expression of CaSR protein when compared to 
others in which the expression of CaSR at protein level appeared to be lower. Similarly, 
the expression of PTH protein was evaluated in all the clones stably transfected with 
CaSR and PTH genes as well as in the clones stably transfected only with PTH gene. 
Once more, the expression level of PTH protein was higher in some of the clones and 
lower in others.  
From the two CaSR stably transfected clones, clone B6 appeared to have a better 
expression of CaSR protein, it showed a good expression of the CaSR at intracellular 
level and also in the plasmatic membrane of the cell surface. The clone D12 seemed to 
have a lower expression of the CaSR protein either at intracellular level as well as at 
the cell surface. None of the two clones showed any differences in the protein 
expression levels of CaSR protein with the changes in Ca2+0 concentrations. 
In what regards the four clones transfected both with CaSR and PTH genes, three of 
the four clones presented a good expression level of CaSR and PTH proteins. The 
clones C8, G5 and D11 showed a good staining for the intracellular CaSR as well as for 
the CaSR located in the cell surface, indicating that the receptor appears to be 
expressed both at intracellular and cell surface level, in these three double clones. 
Similarly, PTH protein seemed to be well expressed in the double clones C8, G5 and 
D11. The clone B9 showed a slightly lower expression of CaSR protein at both 
intracellular and cell surface locations, as well as a lower expression of PTH protein. 
There were not observed any variations for CaSR protein expression level with the 
changes in Ca2+0 concentrations. However, the clones C8 and G5, stably transfected 
with both CaSR and PTH genes, presented varied levels of PTH protein expression with 
the changes in Ca2+0 concentrations. The immunofluorescent stainings for the clones 
C8 and G5 with a primary antibody anti-PTH revealed lower expression level of PTH at 
hypocalcemia, which increased with normocalcemia and increased even further with 
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hypercalcemia. The clones B9 and D11 did not show any differences in the pattern of 
expression of PTH protein independently from the Ca2+0 concentrations.  
All the nine clones stably transfected with the PTH gene were studied by 
immunofluorescence staining with a primary anti-PTH antibody, to evaluate PTH 
protein expression levels. From these nine clones, two were selected, clone A6 and 
clone D12, due to the high levels of PTH protein expression present. None of the nine 
clones stably transfected with PTH gene showed any differences in PTH protein pattern 
of expression, independently from the Ca2+0 concentrations.  
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Figure 28. Immunofluorescence staining for CaSR protein in the clone B6, stably transfected with the 
CaSR gene. It was analysed the level of expression for the intracellular CaSR (A, B and C) and also for the 
CaSR expressed in the plasmatic membrane of the cell surface (D, E and F). In addition, CaSR protein 
expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), normocalcemia (1,2mM Ca
2+
) 
(B and E) and hypercalcemia (3mM Ca
2+
) (C and F). CaSR is stained in green and nuclei in red. 
Magnification 10x. Images were acquired in a Laser Scanning Confocal Microscope (LSMC).  
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Figure 29. Immunofluorescence staining for CaSR protein in the clone D12, stably transfected with 
CaSR gene. It was analysed the level of expression for the intracellular CaSR (A, B and C) and also for the 
CaSR expressed in the plasmatic membrane of the cell surface (D, E and F). In addition, CaSR protein 
expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), normocalcemia (1,2mM Ca
2+
) 
(B and E) and hypercalcemia (3mM Ca
2+
) (C and F). CaSR is stained in green and nuclei in red. 
Magnification 10x. Images were acquired in a LSMC. 
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Figure 30. Immunofluorescence staining for CaSR protein in the clone B9, stably transfected with both 
CaSR and PTH genes. It was analysed the level of expression for the intracellular CaSR (A, B and C) and 
also for the CaSR expressed in the plasmatic membrane of the cell surface (D, E and F). In addition, CaSR 
protein expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), normocalcemia 
(1,2mM Ca
2+
) (B and E) and hypercalcemia (3mM Ca
2+
) (C and F). CaSR is stained in green and nuclei in 
red. Magnification 10x. Images were acquired in a LSCM. 
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Figure 31. Immunofluorescence staining for PTH protein in the clone B9, stably transfected with both 
CaSR and PTH genes. It was analysed the level of expression for the intracellular PTH (A, B, C, D, E and 
F). In addition, PTH protein expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), 
normocalcemia (1,2mM Ca
2+
) (B and E) and hypercalcemia (3mM Ca
2+
) (C and F). PTH is stained in green 
and nuclei in red. Magnification 10x. Images acquired in a LSCM. 
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Figure 32. Immunofluorescence staining for CaSR protein in the clone C8, stably transfected with both 
CaSR and genes. It was analysed the level of expression for the intracellular CaSR (A, B and C) and also 
for the CaSR expressed in the plasmatic membrane of the cell surface (D, E and F). In addition, CaSR 
protein expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), normocalcemia 
(1,2mM Ca
2+
) (B and E) and hypercalcemia (3mM Ca
2+
) (C and F). CaSR is stained in green and nuclei in 
red. Magnification 10x. Images were acquired in a LSCM. 
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Figure 33. Immunofluorescence staining for CaSR protein in the clone C8, stably transfected with both 
CaSR and genes. It was analysed the level of expression for the intracellular CaSR (A, B and C) and also 
for the CaSR expressed in the plasmatic membrane of the cell surface (D, E and F). In addition, CaSR 
protein expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), normocalcemia 
(1,2mM Ca
2+
) (B and E) and hypercalcemia (3mM Ca
2+
) (C and F). CaSR is stained in green and nuclei in 
red. Magnification 40x. Images were acquired in a LSCM. 
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Figure 34. Immunofluorescence staining for PTH protein in the clone C8, stably transfected with both 
CaSR and PTH genes. It was analysed the level of expression for the intracellular PTH (A, B, C, D, E and 
F). In addition, PTH protein expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), 
normocalcemia (1,2mM Ca
2+
) (B and E) and hypercalcemia (3mM Ca
2+
) (C and F). CaSR is stained in green 
and nuclei in red. Magnification 10x and 40x. Images acquired in a LSCM. 
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Figure 35. Immunofluorescence staining for CaSR protein in the clone D11, stably transfected with 
both CaSR and genes. It was analysed the level of expression for the intracellular CaSR (A, B and C) and 
also for the CaSR expressed in the plasmatic membrane of the cell surface (D, E and F). In addition, CaSR 
protein expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), normocalcemia 
(1,2mM Ca
2+
) (B and E) and hypercalcemia (3mM Ca
2+
) (C and F). CaSR is stained in green and nuclei in 
red. Magnification 10x. Images were acquired in a LSCM. 
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Figure 36. Immunofluorescence staining for CaSR protein in the clone D11, stably transfected with 
both CaSR and PTH genes. It was analysed the level of expression for the intracellular CaSR (A, B and C) 
and also for the CaSR expressed in the plasmatic membrane of the cell surface (D, E and F). In addition, 
CaSR protein expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), normocalcemia 
(1,2mM Ca
2+
) (B and E) and hypercalcemia (3mM Ca
2+
) (C and F). CaSR is stained in green and nuclei in 
red. Magnification 40x. Images were acquired in a LSCM. 
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Figure 37. Immunofluorescence staining for PTH protein in the clone D11, stably transfected with both 
CaSR and PTH genes. It was analysed the level of expression for the intracellular PTH (A, B, C, D, E and 
F). In addition, PTH protein expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), 
normocalcemia (1,2mM Ca
2+
) (B and E) and hypercalcemia (3mM Ca
2+
) (C and F). PTH is stained in green 
and nuclei in red. Magnification 10x and 40x. Images acquired in a LSCM. 
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Figure 38. Immunofluorescence staining for CaSR protein in the clone G5, stably transfected with both 
CaSR and PTH genes. It was analysed the level of expression for the intracellular CaSR (A, B and C) and 
also for the CaSR expressed in the plasmatic membrane of the cell surface (D, E and F). In addition, CaSR 
protein expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), normocalcemia 
(1,2mM Ca
2+
) (B and E) and hypercalcemia (3mM Ca
2+
) (C and F). CaSR is stained in green and nuclei in 
red. Magnification 10x. Images were acquired in a LSCM. 
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Figure 39. Immunofluorescence staining for CaSR protein in the clone G5, stably transfected with both 
CaSR and PTH genes. It was analysed the level of expression for the intracellular CaSR (A, B and C) and 
also for the CaSR expressed in the plasmatic membrane of the cell surface (D, E and F). In addition, CaSR 
protein expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), normocalcemia 
(1,2mM Ca
2+
) (B and E) and hypercalcemia (3mM Ca
2+
) (C and F). CaSR is stained in green and nuclei in 
red. Magnification 40x. Images were acquired in a LSCM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C 
D E F 
92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 40. Immunofluorescence staining for PTH protein in the clone G5, stably transfected with both 
CaSR and PTH genes. It was analysed the level of expression for the intracellular PTH (A, B, C, D, E and 
F). In addition, PTH protein expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), 
normocalcemia (1,2mM Ca
2+
) (B and E) and hypercalcemia (3mM Ca
2+
) (C and F). PTH is stained in green 
and nuclei in red. Magnification 10x and 40x. Images acquired in a LSCM. 
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Figure 41. Immunofluorescence staining for PTH protein in the clone D12, stably transfected with PTH 
gene. It was analysed the level of expression for the intracellular PTH (A, B, C, D, E and F). In addition, 
PTH protein expression level was determined in hypocalcemia (0,1mM Ca
2+
) (A and F), normocalcemia 
(1,2mM Ca
2+
) (B and E) and hypercalcemia (3mM Ca
2+
) (C and F). PTH is stained in green and nuclei in 
red. Magnification 10x and 40x. Images acquired in a LSCM. 
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4.10. Study of PTH secretion and intracellular PTH levels 
In order to determine if the clones stably transfected with both CaSR and PTH genes 
were able to sense the changes in Ca2+0 concentrations and to modulate PTH secretion 
and intracellular levels of PTH, two of the clones (C8 and G5) were stimulated with low 
(0,1mM), physiological (1,2mM) and high (3mM) Ca2+0 concentrations for 1 hour and 
the level of intracellular and secreted PTH were determined with a rat PTH ELISA kit.  
The clones C8 and G5 were chosen given the results obtained with the analysis of PTH 
protein levels with immunofluorescence staining, which showed a possible ability of 
the CaSR stably transfected in these two clones, to modulate intracellular levels of PTH 
and PTH secretion given the higher expression of intracellular PTH protein seen at 
higher Ca2+0 concentrations.  
The rat PTH ELISA kit revealed increased concentrations of intracellular PTH with the 
increase of Ca2+0 levels for the clone C8. The increase of intracellular PTH 
concentrations from 0,1mM Ca2+ (96pg/ml) to 3mM Ca2+ (175pg/ml) showed a 
statistical significance of ρ<0,05. However, the same was not verified for the clone G5, 
which showed a slight decrease in the intracellular concentration of PTH from 0,1mM 
Ca2+ to 1,2mM Ca2+, even though the intracellular concentration of PTH was increased 
again at 3mM Ca2+. The intracellular levels of PTH showed for the cells transfected with 
the empty plasmid expression vector were not modulated by the Ca2+0 concentrations. 
In addition, the values for the concentrations of intracellular PTH were more elevated 
for both clones C8 and G5 when compared with the low values presented by the cells 
transfected with the empty plasmid expression vector. The clone C8, when compared 
with the cells transfected with the empty plasmid, showed an increase in intracellular 
PTH levels with a statistical significance of ρ<0,01 at 0,1mM Ca2+ and ρ<0,05 at 1,2mM 
and 3mM Ca2+. The clone G5 presented an increase in intracellular PTH levels with a 
statistical significance of ρ<0,01 at 0,1mM Ca2+ and ρ<0,05 at 3mM Ca2+, when 
compared with the cells transfected with the empty plasmid vector. 
In what regards the results obtained for the determination of PTH secretion, the values 
obtained for both the clone C8 and G5 are low and close to the values obtained for the 
cells transfected with the empty plasmid expression vector, without presenting any 
statistical significant differences. 
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Figure 42. Results for the analysis of intracellular levels of PTH modulated by [Ca
2+
0]. 
 
 
 
 
 
Figure 43. Results for the analysis of PTH secretion modulated by [Ca
2+
0]. 
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5. Discussion 
In spite of many attempts from the scientific world, there is yet no continuous 
parathyroid cell line available to study the function and pathologies of this gland. The 
establishment of a parathyroid cell line has been tried mainly with human parathyroid 
cells and bovine parathyroid cells. However, it has proven difficult to maintain human 
or bovine parathyroid cells functional in culture. Primary cultures of human 
parathyroid cells grow slowly and quickly loose the expression of CaSR gene as well as 
the secretion of PTH. Similarly, bovine parathyroid cells in primary culture show a 
decreased expression of CaSR gene and a loss of PTH secretion, after a few days in 
culture [2,3]. In the parathyroid gland, the CaSR has the important role of sensing the 
changes in Ca2+0 and modulate the secretion of PTH hormone. It is responsible for the 
inhibition of PTH secretion when Ca2+0 levels are high [4,6]. Consequently, the loss of 
the expression of these two main genes of the parathyroid gland, as well as the loss of 
the ability of CaSR to modulate the secretion of PTH makes the use of human and 
bovine parathyroid primary cell cultures extremely difficult in the study of parathyroid 
physiology and pathology. Despite these disadvantages primary cultures of bovine 
parathyroid cells and human parathyroid cells have been used to study parathyroid 
gland and its diseases. If it would be possible to establish an epithelial parathyroid cell 
line able to maintain CaSR expression and PTH secretion in long term culture, and 
more importantly, if a continuous parathyroid cell line with PTH secretion regulated by 
changes in Ca2+0 could be established, it would open the boundaries of parathyroid 
research and remarkably improve the study of parathyroid physiology and pathology, 
particularly the study of parathyroid adenomas and carcinomas, in which the 
molecular mechanisms responsible for parathyroid cell proliferation, as well as the 
molecular basis that lead to decreased CaSR expression and abnormal modulation of 
PTH secretion by calcium are still not completely understood.  
The PTH-C1 cell line is a parathyroid cell line derived from rat with qualitative 
expression of several genes related to the parathyroid gland, as well as qualitative 
expression of the two main characteristic genes of parathyroid cells, CaSR and PTH 
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genes. In the laboratory of Prof. Maria Luisa Brandi in the University of Florence, Italy, 
the PTH-C1 was subcloned from the PT-r cell line, a rat epithelial clonal parathyroid cell 
line established in 1987. The expression of PTH was absent in the PT-r cell line, which 
expressed only the parathyroid hormone-related peptide (PTHrP). (167, 168, 170) 
Recently, Kawahara et al. showed that the PT-r cell line has endogenous expression of 
the PTH gene (169). Consequently, the PT-r cell line was cloned in order to isolate one 
clone with expression of PTH, which was named PTH-C1. However, the expression level 
of the CaSR and PTH genes in the PTH-C1 is low and the modulation of PTH secretion 
by Ca2+0 is absent in this cell line. Therefore, the CaSR and PTH genes were stably 
transfected in the PTH-C1 cell line in order to create PTH-C1 cell clones with stable 
expression of the CaSR gene, the PTH gene and both CaSR and PTH genes. 
Subsequently, PTH-C1 cell clones with stable expression of CaSR gene, PTH gene and 
both CaSR and PTH genes were isolated from the heterogeneous populations of PTH-
C1 cells stably transfected with CaSR and/or PTH genes. The expression level of CaSR 
and PTH genes in the obtained clones was then characterized at mRNA and protein 
level. Furthermore, the role of CaSR gene in cell proliferation was studied in the 
obtained clones stably transfected with CaSR and/or PTH genes. Finally, it was studied 
if the secretion of PTH and the intracellular level of PTH were regulated by Ca2+0 in the 
clones stably expressing both CaSR and PTH genes. 
5.1. Stable Transfection 
The first step of stable transfection consisted in selecting an adequate plasmid 
expression vector able to stably transfect PTH-C1 cells. The pcDNA3.1/Zeo(+) plasmid 
expression vector was chosen due to its ability to stably transfect mammalian cells, its 
strong CMV promoter that provides high expression level of the gene inserted on the 
plasmid vector and because of the multiple cloning sites placed in a favorable 
orientation to the insertion of the genes to be cloned. More importantly, the 
pcDNA3.1/Zeo(+) plasmid expression vector contains a Zeocin selection marker that 
confers resistance to the antibiotic Zeocin to the cells that have stably integrated the 
gene of interest in the chromosomal DNA, allowing the separation and selection of the 
stably transfected cells from the non-transfected ones. Furthermore, the antibiotic 
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Zeocin belongs to the bleomycin/phleomycin family, which does not present any 
known interactions with the CaSR, contrary with other antibiotics such as neomycin, an 
aminoglycoside antibiotic widely used as a selection marker that is known to stimulate 
the CaSR.  
Once the adequate plasmid expression vector was chosen, the CaSR gene was inserted 
in the pcDNA3.1/Zeo(+) plasmid vector and simultaneously, the PTH gene was inserted 
in another pcDNA3.1/Zeo(+) plasmid vector. Therefore, the CaSR gene inserted in the 
p-sport bacterial plasmid vector was removed by digestion with the appropriated 
restriction enzymes (NotI/KpnI/PvuI) and inserted with a ligation reaction in the 
pcDNA3.1/Zeo(+) plasmid expression vector previously digested with the same 
restriction enzymes (NotI/KpnI). Simultaneously, the rat PTH gene bought from 
Genscript was removed from the pUC57 with restriction enzymes to the restriction 
sites of HindIII/EcoRI and inserted in another pcDNA3.1/Zeo(+) plasmid expression 
vector, previously digested with HindIII/EcoRI restriction enzymes. Subsequently, the 
transient transfections were performed in the PTH-C1 cells in order to establish the 
optimal quantities of plasmid DNA and Attractene transfection reagent to be used in 
stable transfection and to determine if the CaSR and PTH plasmids constructed were 
functioning properly and able to perform a transient transfection, as well as to 
determine if PTH-C1 cells could be transfected. The transient transfections of PTH-C1 
cells was successful, has was showed by the transient overexpression of CaSR and PTH 
mRNA transiently transfected separately or together in the PTH-C1 cells. The success of 
transient transfections indicated that both CaSR pcDNA3.1/Zeo(+) and PTH 
pcDNA3.1/Zeo(+) plasmid expression vectors constructed were functioning properly 
and that PTH-C1 cells were able to be transiently transfected. The final step before 
proceed to the stable transfection of PTH-C1 cells was the determination of the 
optimal concentration of the antibiotic Zeocin to be used in the selection of the clones 
stably transfected.  
Once the optimal quantities of plasmid DNA and transfection reagent and the optimal 
concentration of the antibiotic Zeocin had been determined the stable transfection of 
PTH-C1 was performed, leading to four heterogeneous populations of stably 
transfected cells: one first population of cells stably expressing the CaSR gene, a 
second population of cells stably expressing the PTH genes, a third population of cells 
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stably expressing both CaSR and PTH genes and a forth population of cells stably 
transfected with the empty pcDNA3.1/Zeo(+) plasmid expression vector. Hereafter, the 
three heterogeneous populations of cells stably transfected with CaSR and/or PTH 
genes were cloned with the aim of isolating single clones stably overexpressing 
separately the CaSR gene or the PTH gene and a clone stably overexpressing both CaSR 
and PTH genes together. The cloning was successful and were obtained: two clones 
stably expressing the CaSR gene, four clones stably expressing both CaSR and PTH 
genes and nine clones stably expressing the PTH gene. 
5.2. Characterization of the stably transfected clones 
All the clones obtained with the stable transfection of CaSR and/or PTH genes in the 
PTH-C1 cells were characterized both at mRNA and protein levels. 
5.2.1. Characterization of the stably transfected clones at mRNA level 
The expression level of CaSR and PTH genes in the mRNA of PTH-C1 cells was 
qualitatively characterized, by PCR reaction, in order to determine which clones had 
been able to integrate the CaSR and PTH genes, alone or together, in the chromosomal 
DNA of the PTH-C1 cells. All the clones considered stably transfected presented the 
bands of appropriated height corresponding to the CaSR or the PTH genes, in contrast 
with the cells stably transfected with the empty pcDNA3.1/Zeo(+) plasmid vector, 
where the PCR bands for CaSR and PTH genes were absent. Furthermore, all the 
obtained clones were sequenced for rat CaSR and rat PTH full length genes with the 
aim of verifying further if the bands obtained by PCR corresponded to CaSR and PTH 
genes. The sequencing results revealed 100% of homology between the cDNA 
sequences of CaSR and PTH genes obtained from the several clones and the cDNA 
sequences of rat CaSR and rat PTH genes reported in GENEBANK with Blast. 
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5.2.2. Characterization of the stable transfected clones at protein level 
 
Once the stable integration of the CaSR gene, the PTH gene or both CaSR and PTH 
genes in the chromosomal DNA of the PTH-C1 cells had been verified, the obtained 
clones were further characterized at protein level. Immunofluorescence staining with 
primary antibodies anti-CaSR and anti-PTH were used to stain CaSR and PTH proteins 
in the obtained clones. The aim was to determine if PTH-C1 cell clones stably 
transfected with CaSR and PTH genes were able to translate the two genes expressed 
at mRNA level into protein at the obtained clones stably transfected, as well as to 
determine the protein level of expression of the two genes.  
The expression of the CaSR at protein level inside the cell, in the cytoplasm, was 
studied in all the clones stably transfected with the CaSR and in the clones stably 
transfected with both CaSR and PTH genes. In addition, the location of the CaSR in the 
plasmatic membrane of the cell surface was also determined. The expression of CaSR 
protein was present both in the cell surface as well as at intracellular level and similar 
levels of CaSR protein were showed both intracellularly and in the plasmatic 
membrane of the cell surface, in all the stably transfected clones. Furthermore, with 
the goal of determining if CaSR protein expression levels were affected by variations in 
the Ca2+0, expression levels of CaSR protein were studied in hypocalcemia (0,1mM 
Ca2+), normocalcemia (1,2mM Ca2+) and hypercalcemia (3mM Ca2+). As was expected, 
no differences in CaSR pattern of protein expression were seen either in the CaSR 
located intracellularly or in the cell surface, independently from Ca2+0 concentrations. 
This result was expected since there are presently no reports in published literature 
indicating that CaSR protein expression levels changes with variations in Ca2+0  
concentrations.  
In spite of all the clones stably transfected with the CaSR or with both CaSR and PTH 
genes showed expression of CaSR protein either intracellularly and in the cell surface, 
CaSR protein was not equally expressed in all the clones. In what regards the two 
clones stably transfected with the CaSR gene, the clone B6 presented a better 
expression of the CaSR protein than clone D12, visible from the more intense and 
defined staining obtained for the CaSR in the clone B6. Similarly, three of the four 
clones stably transfected with both CaSR and PTH genes presented a better expression 
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of CaSR protein. Clones C8, D11 and G5 showed a good staining for the CaSR both at 
intracellular and cell surface levels, with good intensity and detailed definition. In 
contrast, the clone B9 showed a poorer staining for the CaSR either intracellularly as 
well as in the plasmatic membrane. All the clones showed almost any 
immunofluorescence in the negative control of the CaSR protein.  
In what regards the level of expression of PTH protein in the clones stably transfected 
with the PTH gene or with both CaSR and PTH genes, the level of expression varies 
between clones, similarly to what was described for the expression of CaSR protein. 
Two clones named A6 and D12 were selected from the nine obtained clones with 
stable expression of the PTH gene, due to the well expressed PTH protein in these 
clones. It was studied if PTH protein expression was influenced by changes in Ca2+0 
concentrations, in the clone D12, which presented a good expression level of PTH 
protein. However, no changes in the expression level of PTH protein were showed in 
the clone D12, independently from Ca2+0 concentrations. These results were expected 
since this clone was only stably transfected with the PTH gene and the endogenous 
expression of CaSR gene in the PTH-C1 is low. Also, the endogenous CaSR is not able to 
modulate PTH secretion or PTH synthesis in the PTH-C1 cell line. In contrast, clones C8 
and G5, with stable overexpression of both CaSR and PTH genes, showed an increase in 
PTH protein expression levels with the increase in Ca2+0 concentrations. The staining 
for PTH protein in these two clones was lower with hypocalcemia (0,1mM Ca2+), 
increased with physiological levels of calcium (1,2mM ca2+) and increased even further 
with hypercalcemia (3mM Ca2+). These results may indicate that the CaSR stably 
transfected in these two clones is able to modulate the secretion of PTH in response to 
changes in Ca2+0 concentrations. In parathyroid gland, the CaSR senses the variations in 
Ca2+0 levels, leading to prompt inhibition of PTH secretion when extracellular levels of 
calcium are high. If elevated levels of Ca2+ persist for longer periods of time, PTH 
synthesis is also inhibited. Consequently, when the extracellular levels of c Ca2+ are 
low, PTH secretion persists, as well as PTH synthesis if hypocalcemia is maintained 
overtime. However, the cells stained for PTH protein had been stimulated with 
different Ca2+0 concentrations only for 72h, which is not a period of time long enough 
to increase PTH synthesis or intracellular stores of PTH protein, when the calcium is 
low. Similarly, 72h of stimulation is not enough to increase the degradation of 
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intracellular PTH stores, when the CaSR is high.  In this view, the CaSR stably 
transfected in the clones C8 and G5 may be able to inhibit PTH secretion since the 
expression of intracellular PTH protein is lower when the cells were stimulated with 
low Ca2+0 concentration for a short period of time (72h), when compared with the 
higher expression of PTH protein obtained after stimulate the cells with higher Ca2+0 
concentrations for the same period of time. Therefore, the higher expression of PTH 
protein seen at high Ca2+ may represent the PTH stored in intracellular vesicles. The 
other two clones, B9 and D11, with stable expression of both CaSR and PTH genes did 
not show any differences in PTH protein expression, independently from Ca2+0 
concentrations, even if clone D11 presented good expression levels of both CaSR and 
PTH protein. In contrast, clone B9 showed minor protein expression levels of PTH and 
also CaSR, as was already discussed. All the clones showed almost any 
immunofluorescence in the negative control of PTH protein.  
In conclusion, the clone B6, with stable expression of the CaSR gene, showed a better 
level of CaSR protein expression than the other clone stably transfected with the CaSR 
gene. Identically, the clones C8 and G5 with stable expression of both CaSR and PTH 
genes, presented better protein expression levels of CaSR and PTH and are possibly 
able to sense changes in Ca2+0 and modulate PTH intracellular levels accordingly. The 
same was not verified for clones B9 and D11 with stable expression of both CaSR and 
PTH genes. Finally, clone D12, with stable expression of the PTH gene, showed a good 
staining for PTH protein but there were not observed any changes in PTH protein 
expression levels, independently from Ca2+0 levels. 
5.3. Study of cell proliferation 
Parathyroid adenomas and hyperplastic parathyroid glands are frequent pathologies of 
the parathyroid gland that present abnormal parathyroid cell proliferation. Similarly, 
uncontrolled parathyroid cell proliferation is seen in parathyroid carcinomas, an 
extremely rare type of carcinoma. Interestingly, the CaSR has been related to the 
development and progression of abnormal parathyroid cell proliferation. In normal 
parathyroid glands, parathyroid cell proliferation is slow and the CaSR is well expressed 
at mRNA and protein level. However, in parathyroid tumourigenesis the expression of 
the CaSR is decreased or absent at mRNA and protein level and parathyroid cell 
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proliferation increases, leading to an increase in parathyroid cell mass that 
characterizes parathyroid adenomas and carcinomas. Therefore, in parathyroid 
tumourigenesis, the receptor appears to act as a tumour suppressor gene, able to 
inhibit parathyroid cell proliferation when is expressed at physiological levels and 
unable to suppress parathyroid cell proliferation when its expression levels decrease in 
pathological conditions. Consequently, since the PTH-C1 cell line endogenously 
expresses the CaSR gene at low expression levels, in contrast with the clones stably 
transfected with the CaSR or with both CaSR and PTH genes, which present the CaSR 
overexpressed, it was hypothesized that the CaSR overexpressed in the stable clones 
might have a role in the proliferation of the PTH-C1 cell line. In order to study the 
possible role of the CaSR in the inhibition of PTH-C1 cell proliferation, cell proliferation 
of the clones stably transfected with the CaSR gene, with both CaSR and PTH genes 
and with the PTH gene were studied and compared to cell proliferation of PTH-C1 cells 
transfected with the empty plasmid expression vector. Furthermore, the study of cell 
proliferation was performed upon stimulation of the clones stably transfected with the 
CaSR and/or PTH genes, as well as the cells stably transfected with the empty plasmid, 
with low calcium concentrations (0,1mM Ca2+), physiological Ca2+ concentrations 
(1,2mM Ca2+) and high Ca2+ concentrations (3mM Ca2+). It was expected to observe a 
decrease in cell proliferation rate when the clones with stable expression of the CaSR 
gene were stimulated with high levels of Ca2+0, able to activate the CaSR in a similar 
manner seen in in vivo models of primary and secondary hyperparathyroidism treated 
with calcimimetics. Cell proliferation was studied with the measurement or 3H – 
Thymidine incorporation and the construction of growth curves. 
5.3.1. Study of cell proliferation with 3H – Thymidine 
The first approach in the study of cell proliferation consisted in measuring the 
incorporation of 3H – Thymidine in the clones stably transfected with the CaSR and 
with both CaSR and PTH genes, as well as in the cells transfected with the empty 
plasmid expression vector. The incorporation of 3H – Thymidine in the newly 
synthesized DNA by the substitution of the nucleotide thymidine by a nucleotide of 
thymidine labeled with the radioactive hydrogen (3H), allows the subsequent 
measurement of the radioactivity emitted in a scintillation beta-counter that is a 
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representative measure of the amount of DNA newly synthesized, which is in turn, an 
approximate measure of cell proliferation. The incorporation of 3H – Thymidine was 
used as a screening method in order to determine which clones might present a slower 
rate of growth when stimulated with low concentrations of calcium (0,12mM Ca2+), 
physiological levels of calcium (1,2mM Ca2+) and high concentrations of calcium (3mM 
Ca2+). The incorporation of 3H – Thymidine was also tested in the cells stably 
transfected with the empty vector and equally stimulated with low, physiological and 
high Ca2+ concentrations.  
The clones B6 and D12, stably transfected with the CaSR gene and the clone C8, stably 
expressing both CaSR and PTH genes, presented a statistical significant decrease in the 
incorporation of 3H – thymidine after stimulation with high Ca2+0 concentrations 
(3mM) compared with the values obtained with lower Ca2+0 concentrations (0,1mM 
and 1,2mM). Therefore, the screening with incorporation of 3H – thymidine appeared 
to indicate a decrease in DNA synthesis, and consequently a decrease in cell 
proliferation, for the clones B6, D12 and C8 stimulated with high concentrations of 
Ca2+ in respect to its stimulation with lower levels of calcium. These results seemed to 
indicate that the CaSR activated by high Ca2+ concentrations was able to suppress 
parathyroid cell proliferation, while at lower concentrations of Ca2+ the receptor was 
not stimulated to inhibit cell proliferation. However, these results were not supported 
by the results obtained with the growth curves. The other clone studied, G5, with 
stable expression of both CaSR and PTH genes did not show any differences in the 
incorporation of 3H – thymidine, independently from the Ca2+0 concentrations and, the 
same was seen for the cells stably transfected with the empty plasmid expression 
vector, as was expected due to the low expression of the endogenous CaSR gene in the 
PTH-C1 cells.  
5.3.2. Study of cell proliferation with growth curves 
In simultaneous with the study of incorporation of 3H – thymidine, cell proliferation 
was studied with the construction of growth curves. The two clones stably transfected 
with the CaSR gene, the four clones stably transfected with both CaSR and PTH genes, 
one of the nine clones stably transfected with the PTH gene and the cells stably 
transfected with the empty plasmid expression vector were growth in hypocalcemia 
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(0,1mM Ca2+), normocalcemia (1,2mM Ca2+) and hypercalcemia (3mM Ca2+) and 
growth curves were constructed. The cell population doubling time were determined 
and statistically compared.  
In contrast with the results obtained with the incorporation of 3H – thymidine, none of 
the clones tested revealed a decrease in the rate of cell proliferation, independently 
from the Ca2+0 concentrations. The results of the growth curves appear to indicate that 
the CaSR stably overexpressed in the PTH-C1 cell clones is not able to inhibit cell 
proliferation when stimulated with high Ca2+0 concentrations. The incorporation of 
3H 
– thymidine is considered mainly a screening method, which is not as specific and 
robust as the construction of growth curves in the study of cell proliferation. 
Consequently, in spite of the results obtained with the incorporation of 3H – thymidine 
have showed a statistical significant reduction in cell proliferation in some of the CaSR 
stably transfected clones stimulated with high Ca2+0 concentrations, it is concluded 
that the CaSR stably transfected in the PTH-C1 cell clones is not able to suppress cell 
proliferation when stimulated with high Ca2+0  concentrations since the results 
obtained with the incorporation of 3H – thymidine were not confirmed by the results 
obtained with the construction of growth curves. 
Furthermore, the cell population doubling times obtained for the clones stably 
transfected with CaSR and/or PTH genes growth in hypocalcemia (0,1mM Ca2+), 
normocalcemia (1,2mM Ca2+) and hypercalcemia (3mM Ca2+) were statistically 
compared with the cell population doubling times obtained for the cells stably 
transfected with the empty plasmid expression vector, growth in hypocalcemia 
(0,1mM Ca2+), normocalcemia (1,2mM Ca2+) and hypercalcemia (3mM Ca2+), in order 
to verify if the CaSR stably overexpressed in the PTH-C1 cell clones was able to increase 
cell population doubling times of the clones stably transfected with the CaSR. From all 
the clones tested, only one of the clones presented cell population doubling times 
statistically higher than the cell population doubling times obtained for the cells stably 
transfected with the empty plasmid expression vector, in low, physiological and high 
Ca2+0 concentrations. The clone B6, with stable overexpression of the CaSR gene, 
showed increased cell population doubling times when growth in hypocalcemia, 
normocalcemia or hypercalcemia, indicative of a slower rate of cell proliferation. 
Consequently, the CaSR gene stably integrated in the chromosomal DNA of the clone 
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B6 seems to be able to decrease cell proliferation, when compared with the PTH-C1 
cells stably transfected with the empty plasmid. This result supports the role of the 
CaSR as a tumour suppressor gene, seen in parathyroid tumours. Since the clone B6 
has stable overexpression of the CaSR gene, in contrast with the PTH-C1 cells stably 
transfected with the empty plasmid, which possess endogenously the CaSR gene 
expressed at low levels, can be hypothesized that the CaSR stably transfected in the 
clone B6 is able to decrease cell proliferation due to its high levels of expression. 
Although, the possible differences in the levels of expression of the CaSR gene have 
not been experimentally studied it is interesting to speculate that the CaSR stably 
transfected in the clone B6 might be expressed at higher levels than the CaSR gene 
stably transfected in the other obtained clones. The higher expression levels of the 
CaSR in clone B6 would provide a possible explanation for the fact that this clone was 
the only to show a decrease in cell proliferation. This supports the theory that the 
decreased or lost expression levels of the CaSR seen in parathyroid tumours might 
have a role in the development of parathyroid hyperplasia and cancer.  
In conclusion, in spite of none of the clones stably overexpressing the CaSR gene 
showed decreased cell proliferation, independently from the Ca2+0 concentrations, the 
clone B6 with stable overexpression of the CaSR gene showed a slower rate of growth 
when compared with the PTH-C1 cells stably transfected with the empty plasmid 
expression vector.  
5.4. Study of PTH secretion and intracellular PTH levels 
In normal parathyroid glands, the CaSR senses the changes in Ca2+0 levels and 
modulates the secretion of PTH, the intracellular levels of PTH and the synthesis of PTH 
in response to the changes in the Ca2+0 levels. However, in pathological parathyroid 
glands, such as parathyroid adenomas and carcinomas, is seen an abnormal PTH 
secretion in response to Ca2+0, in which the secretion of PTH is deregulated from Ca
2+
0 
concentrations. Given that, the PTH-C1 cell line with low endogenous expression of 
CaSR and PTH mRNA and protein does not present PTH levels regulated by Ca2+0 
concentrations, PTH-C1 cells stably transfected with the empty plasmid were 
considered to be an in vitro cell model of parathyroid tumourigenesis and the clones 
stably transfected with both CaSR and PTH genes were considered to be similar to the 
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normal parathyroid glands. Therefore,  in order to determine if the clones C8 and G5, 
stably transfected with both CaSR and PTH genes, were able to sense the changes in 
Ca2+0 concentrations and modulate PTH secretion, as well as intracellular PTH levels, 
accordingly, variations in PTH secretion and intracellular PTH levels were measured 
with a rat PTH ELISA kit after stimulate the clones in hypocalcemia (0,12mM Ca2+), 
normocalcemia (1,2mM Ca2+) and hypercalcemia (3mM Ca2+) for 1 hour and 72h, 
respectively, and compared to the levels of intracellular PTH and secreted PTH 
obtained for the cells transfected with the empty plasmid expression vector. The 
clones C8 and G5 were selected from the four clones with stable overexpression of 
both CaSR and PTH genes because the results obtained with the characterization of 
PTH protein levels of the stably transfected clones, in immunofluorescence staining, 
showed that the CaSR stably transfected in the clones C8 and G5 was possibly able to 
sense changes in Ca2+0 and modulate PTH intracellular levels accordingly. 
The results obtained for the concentrations of intracellular PTH for the clone C8 were 
in accordance with the results obtained previously for the levels of PTH vesicles, in 
immunofluorescence staining. However, the same was not verified for the clone G5. 
The clone C8 showed an increase in intracellular concentrations of PTH with the 
increase in Ca2+0 concentration, with a statistical significance of ρ<0,05. This result was 
unexpected because in normal parathyroid cells, high levels of Ca2+0 induce decreased 
levels of PTH secretion, as well as decreased intracellular PTH levels due to decreased 
PTH synthesis and increased PTH defradation. The results obtained for the clone C8, 
with stable overexpression of both CaSR and PTH genes, show an increase in the 
intracellular levels of PTH with high Ca2+0 concentrations, which is the contrary of what 
is seen in normal parathyroid cells. However, the clone C8 was stimulated with Ca2+0 
concentrations (0,1mM; 1,2mM; 3mM) for a short period of time (72h). Since the clone 
C8 was stimulated in hypocalcemia only for 72h, possibly, it cannot be considered a 
sufficiently long time to stimulate an increase in PTH synthesis and subsequently in the 
amount of intracellular PTH protein, characteristic of the long-term stimulation with 
low Ca2+0 levels. Similarly, possibly the stimulation of the clone C8 in hypercalcemia for 
the time period of 72h is not sufficiently long to induce decrease PTH synthesis and 
degradation of intracellular PTH stores, which could justify the high levels of 
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intracellular PTH obtained at high Ca2+0 concentrations. Still, the results indicate that 
the clone C8 appears to be able to sense changes in Ca2+0 concentrations.  
In order to support further that the clone C8 is able to sense extracellular changes in 
calcium concentrations, PTH secretion should also be modulated accordingly. 
However, the clone C8 showed low levels of PTH secretion that were independent 
from Ca2+0 concentrations and were similar to the PTH secretion levels obtained for the 
cells transfected with the empty plasmid expression vector. Similar results were 
obtained for the clone G5. The levels of PTH secretion obtained for the cells 
transfected with the empty plasmid expression vector were low and independent from 
the concentrations of Ca2+0, as was expected due to the low expression levels of the 
endogenous CaSR present in the PTH-C1 cells. 
5.5. Final discussion and conclusions 
The attempt to stably transfect the PTH-C1 cell line with CaSR and PTH genes was 
successful and lead to the establishment of a rat parathyroid cell line with stable 
overexpression of CaSR and PTH genes. This constitutes an extremely valuable 
achievement for the future studies of physiology and pathology of the parathyroid 
gland due to the current lack of a continuous parathyroid cell line with expression of 
CaSR and PTH genes, the main important genes of this endocrine gland. The stable 
transfection lead to the achievement of several clones stably transfected with the CaSR 
and/or PTH genes: two clones stably transfected with the CaSR gene, four clones stably 
transfected with both CaSR and PTH genes and nine clones stably transfected with the 
PTH gene. The characterization of the obtained clones at protein level allowed the 
differentiation of the clones with better expression levels of CaSR and PTH proteins. 
The further characterization of the clones with the analysis of cell proliferation allowed 
to select one clone, the clone B6, stably overexpressing the CaSR gene, with slower cell 
rate of growth when compared with the cells stably transfected with the empty 
plasmid expression vector, which present endogenous CaSR low expression levels. 
However, any of the clones stably transfected with the CaSR gene or with both CaSR 
and PTH genes presented decreased cell proliferation when stimulated with high 
concentrations of Ca2+0. The study of the ability of CaSR in the clones stably transfected 
with both CaSR and PTH genes to detect changes in concentrations of Ca2+0 and 
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subsequently modulate PTH protein levels in response to the changes in Ca2+0 
concentrations evidenced one clone, the clone C8, with ability to modulate 
intracellular PTH levels. The clone C8 showed increased levels of intracellular PTH with 
increased concentrations of Ca2+0. Even if, this is not what is normally seen in normal 
parathyroid glands, the results might support a role for the CaSR overexpressed in the 
clone C8 to modulate intracellular PTH levels in response to Ca2+0, since the cells were 
stimulated for a short period of time (72h) with low, physiological and high Ca2+0 levels, 
which may not be a time period sufficiently long to increase PTH synthesis and 
subsequently, increase PTH intracellular levels when Ca2+0 is low.  Similarly, 72h are 
probably a short time period of stimulation with high calcium to observe the results of 
decreased PTH synthesis and increase PTH degradation in intracellular PTH levels. In 
order to further confirm the obtained results PTH secretion levels should be analysed 
and high and low levels of PTH secretion should be obtained with low and high Ca2+0 
concentrations, respectively. However, in the study of PTH secretion performed in this 
work the obtained PTH levels are low or near zero, which could possibly indicate that 
the rat PTH ELISA kit was not able to detect the differences in PTH secretion or that the 
PTH levels present in the samples are low and should be concentrated in order to be 
able to be assayed by the ELISA kit.  
Furthermore, the results obtained for the clone C8 after 72h of stimulation with low, 
physiological and high extracellular calcium concentrations should possibly be 
supported by the results obtained with the stimulation of clone C8 with low, 
physiological and high levels of Ca2+0 concentrations for a long period of time. In this 
case, it would be expected to obtain increased intracellular PTH levels with decreased 
concentrations of Ca2+0. This is because, normal parathyroid cells, when stimulated 
with low Ca2+ for a long period of time show increased synthesis of PTH and increased 
levels of intracellular PTH stores. Likewise, normal parathyroid cells present decreased 
levels of PTH in intracellular stores, due to increased PTH degradation, when are 
stimulated with high levels of Ca2+0  for an appropriately long period of time.  
Nevertheless, the results obtained are encouraging and indicate that clone C8 is able 
to modulate PTH intracellular levels in response to changes in Ca2+0 concentrations.  
In conclusion, the characterization of the obtained clones allowed to select the clone 
B6, with stable overexpression of the CaSR gene; the clone C8, with stable 
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overexpression of both CaSR and PTH genes and the clone D12 with stable 
overexpression of the PTH gene, as the clones with better expression levels of CaSR 
and/or PTH proteins and more favourable characteristics of cell proliferation and 
possible ability to sense and to modulate PTH levels in response to concentrations of 
Ca2+0. 
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6. Conclusion 
The establishment of a continuous parathyroid cell line with overexpression of both 
CaSR and PTH genes was successfully achieved in this work and can provide numerous 
advantages to the future studies of parathyroid physiology and pathology. The 
characterization of the obtained clones stably transfected with CaSR and/or PTH genes 
at mRNA and protein levels showed the achievement of valuable clones with stable 
overexpression of the CaSR gene, both CaSR and PTH genes and of the PTH gene that 
can be used in future studies. The study of cell proliferation revealed the existence of a 
single clone with stable expression of the CaSR gene (clone B6), with slower cell 
proliferation than the cells transfected with the empty plasmid vector, which possess 
low endogenous expression of the CaSR. This result is in agreement with the inhibitory 
role of the CaSR in parathyroid cell proliferation seen in parathyroid hyperplasia and 
tumourigenesis. The analysis of PTH modulation by extracellular calcium 
concentrations revealed that one of the clones stably transfected with both CaSR and 
PTH genes seems to be able to sense the changes in Ca2+0 levels and to modulate 
intracellular PTH levels accordingly. Finally, the characterization of all the obtained 
clones at mRNA and protein levels as well as the results obtained with the study of cell 
proliferation and the study of PTH response to Ca2+0, allowed to select one single clone 
from each of the three types of clones initially obtained: clones with stable expression 
of the CaSR gene, clones with stable expression of both CaSR and PTH genes and 
clones with stable expression of the PTH gene. The clone B6 was selected from the two 
clones stably expressing the CaSR gene due to the demonstrated ability to inhibit cell 
proliferation; the clone C8 was chosen from the four clones stably transfected with 
both CaSR and PTH genes given the results obtained for the modulation of intracellular 
PTH by Ca2+0 concentrations and the clone D12, was selected from the nine clones with 
stable expression of PTH gene due to the good expression levels of the PTH protein 
obtained. Consequently, the clone B6 with stable overexpression of the CaSR gene, the 
clone C8 with stable overexpression of both CaSR and PTH genes and the clone D12 
with stable expression of the PTH gene were selected from all the clones obtained with 
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the stable transfection and are useful in vitro cell models to be used in the future 
studies of parathyroid physiology and pathology.  
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7. Future Research Perspectives 
The most common pathologies of the parathyroid gland are characterized by increased 
cell profileration of the gland. Parathyroid adenomas and parathyroid hyperplasia are 
examples of such parathyroid pathologies and lead to primary and secondary 
hyperparathyroidism, respectively. The study of the development and progression of 
parathyroid tumours has been limited due to the absence of a continuous parathyroid 
cell line. Consequently, the continuous rat parathyroid cell line with stable 
overexpression of CaSR and PTH genes established in this work constitutes one step 
further in the research of the parathyroid gland. Likewise, the development of a 
parathyroid cell line with stable overexpression of the CaSR gene that shows decreased 
cell proliferation when the CaSR is overexpressed provides further support for the 
CaSR known ability to inhibit parathyroid proliferation. However, the fact that high 
levels of Ca2+0 were not able to have an effect in cell proliferation of any of the clones 
stably transfected with the CaSR gene, suggests that it would possibly be interesting to 
verify if allosteric modulators of the CaSR, such as calcimimetics, would also not be 
able to decrease cell proliferation or, in contrary, would induce slow rates of cell 
proliferation in the clones stably transfected with the CaSR gene. Even more 
important, was the establishment of a continuous parathyroid cell line with stable 
overexpression of both CaSR and PTH genes that appears to show intracellular levels of 
PTH regulated in response to extracellular calcium concentrations. The attempts made 
in this work to determine if PTH secretion was also regulated by extracellular 
concentrations of calcium were not successful. In this view, the determination of PTH 
secretion after stimulate the cells with calcimimetics could also be considered as a 
future option. Another important factor to be studied in the established parathyroid 
cell line with stable overexpression of CaSR and PTH genes are intracellular calcium 
levels. It would be interesting to determine if the clone C8, with stable expression of 
both CaSR and PTH genes, which showed intracellular PTH levels regulated by 
extracellular calcium, would also present an increase in intracellular calcium levels with 
high Ca2+0 levels. Finally, in normal human and bovine parathyroid cells the ERK1/2 
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protein was showed to be activated with high Ca2+0 concentrations, in contrast to 
human parathyroid adenomas, where ERK1/2 protein is activated independently from 
Ca2+0 levels. Therefore, it would be interesting to determine if the established 
continuous parathyroid cell line with stable overexpression of both CaSR and PTH 
genes, presents ERK1/2 activated with increased Ca2+0 levels, as is seen in normal 
parathyroid glands or if ERK1/2 protein is activated independently from Ca2+0, similarly 
to parathyroid tumours.    
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